Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год

Применить Всего найдено 3336. Отображено 100.
10-05-2012 дата публикации

Novel method for the synthesis of a trisaccharide

Номер: US20120116065A1
Принадлежит: Glycom AS

The present invention relates to an improved synthesis of a trisaccharide of the formula, novel intermediates used in the synthesis and the preparation of the intermediates.

Подробнее
30-08-2012 дата публикации

Method for the manufacture of 2-fluoro-ara-adenine

Номер: US20120220762A1
Принадлежит: Alcafleu Management GmbH and Co KG

A method is described for the manufacture of pure 2-fluoro-ara-adenine of Formula (I) from 2-fluoro-ara-adenine triacetate using potassium carbonate (K 2 CO 3 ), wherein the 2-fluoro-ara-adenine has a reduced dimer contents, as well as the compound 2-fluoro-ara-adenine having a dimer contents of ≦0.3%.

Подробнее
28-02-2013 дата публикации

Methods for the recovery of hcl and for the production of carbohydrates

Номер: US20130047979A1
Автор: AHARON Eyal, Robert Jansen
Принадлежит: HCL CleanTech Ltd

The invention provides an organic phase composition comprising: a. a first component selected from the group consisting of quaternary amines; b. a second component selected from: b1. The group consisting of category B organic acids; b2. The group consisting of a mixtures of category B organic acids and category C organic acids at a B/C molar ratio of RB/C; and b3. The group consisting of a mixtures of category A organic acids and category C organic acids at an A/C molar ratio of RA/C; c. a third component selected from the group consisting of solvents for said first component and for said second component, wherein (i) all three components are oil-soluble and water-insoluble; (ii) the molar concentration of each of said first component and said second component is greater than 0.6 mol/Kg; (iii) the molar ratio between said second component and said first component is greater than 0.9; (iv) RB/C and RA/c are greater than 2; (v) category A organic acids are selected from the group consisting of poly-aromatic sulfonic acids, naphthalene sulfonic acids and acids with a pKa in the range within +/−0.5 pKa units of that of naphthalene sulfonic acid; (vi) category B organic acids are selected from the group consisting of mono-aromatic sulfonic acids, benzene sulfonic acids, and acids with a pKa in the range within +/−0.5 pKa units of that of benzene sulfonic acid; and (vii) category C organic acids are selected from the group consisting of phosphoric acid esters and acids with a pKa in the range within +/−0.5 pKa units of that of di-octyl esters of phosphoric acid.

Подробнее
21-03-2013 дата публикации

Novel Process for the Recovery of Beta Acetylfuranoside

Номер: US20130072674A1
Принадлежит: Hoffmann-La Roche Inc.

There is provided an improved method for the recovery of residual, unseparated β-ACF from reaction mixtures remaining from an initial synthesis of ACF, which is in particular usable on a large industrial scale, more particularly in the production of capecitabine. 1. A method for recovery of initially not separated β-ACF from mother liquor remaining from the synthesis of ACF , wherein the β-ACF is recovered by a combination of at least one distillation method and at least one chemical reaction step.2. The method according to comprising the following sequential steps:a) Evaporation to less than 1% residual solvent of the mother liquor remaining from an initial synthesis of ACF, to increase the content of residual α/β-ACF from about 8 to 15 weight-% to about 25 to 45 weight-%, followed by distillation to about 60 to 80 weight-% and subsequent crystallization of β-ACF out of the distillate by adding a suitable solvent;b) Chemical conversion of α/β-ACF mixture remaining in the mother liquor of step a), to β-ACF by de-acetylation and subsequent re-acetylation, followed by crystallization of β-ACF by addition of a suitable solvent;c) Optional repetition of step a) and b) in a sequential (clockwise) cyclic process.3. The process according to claim 2 , wherein the distillation to about 60 to 80 weight-% of step a) is carried out at 1 to 3 mbar and 200 to 210° C. heating temperature in a continuous thin-film evaporator.4. The process according to claim 3 , wherein step b) comprises the de-acetylation of α/β-ACF in the presence of a suitable base claim 3 , followed by neutralization with a suitable acid and further followed by the re-acetylation reaction in the presence of suitable base claim 3 , a suitable catalyst and a suitable acetylating agent. This application is a continuation of U.S. application Ser. No. 12/690,167, filed Jan. 20, 2010, now Pending, which claims the benefit of European Patent Application No. 09151384.6, filed Jan. 27, 2009, which is hereby incorporated ...

Подробнее
04-04-2013 дата публикации

POST-SYNTHETIC MODIFICATION OF NUCLEIC ACIDS BY INVERSE DIELS-ALDER REACTION

Номер: US20130085271A1
Принадлежит:

The present invention concerns a method and a kit for the post-synthetic modification of nucleic acids via an inverse Diels-Alder reaction. 1. A method for the post-synthetic modification of nucleic acids , comprising the following steps:(a) preparing norbornene or trans-cyclooctene-modified oligonucleotides(b) preparing modified tetrazines, and(c) reacting the norbornene-modified oligonucleotides with the modified tetrazines via inverse Diels Alder reaction.2. The method of claim 1 , wherein the tetrazines are modified with a compound selected from the group consisting of fluorescent claim 1 , luminescent or phosphorescent dyes claim 1 , and affinity tags.3. The method of claim 1 , wherein the oligonucleotide is singly or multiply modified.4. The method of claim 3 , wherein the oligonucleotide is modified terminally and/or internally.5. The method of claim 4 , wherein the terminal modification is 3′and/or 5′.6. The method of claim 1 , wherein the oligonucleotide has a length between 3 and 500 nucleotides.7. The method of claim 1 , wherein the oligonucleotide is single-stranded or double-stranded DNA or RNA claim 1 , a nucleic acid analog or chimera thereof with DNA and/or RNA or an enyzmatically modified PCR product.9. The method of claim 1 , wherein the tetrazine is labelled with one or more of fluorescent claim 1 , luminescent or phosphorescent dyes claim 1 , or tagged with one or more affinity tags.11. The method of claim 1 , wherein the inverse Diels Alder reaction between the modified oligonucleotide and the modified tetrazin uses equimolar amounts of both components if the oligonucleotide is below 100 nucleotides.12. The method of claim 1 , wherein the inverse Diels Alder reaction between the modified oligonucleotide and the modified tetrazin uses the tetrazine in 2-20-fold excess if the oligonucleotide is larger than 100 nucleotides.13. The method of claim 11 , wherein the inverse Diels Alder reaction takes place between 0 and 100° C. in aqueous media.14. ...

Подробнее
25-04-2013 дата публикации

Synthetic Oligosaccharides for Moraxella Vaccine

Номер: US20130102759A1
Принадлежит:

The present invention provides synthetic lipooligosaccharide (LOS)-based oligosaccharides and conjugates containing various serotype-specific oligosaccharide antigens or various core oligosaccharide structures or motifs corresponding to one or more of the three major serotypes and/or members within a given serotype. The oligosaccharides may be synthesized by a chemical assembly methodology relying on a limited number of monosaccharide and disaccharide building blocks. The invention further provides LOS-based immunogenic and immuno-protective compositions and antibodies derived therefrom for diagnosing, treating, and preventing infections caused by 298-. (canceled) The present invention relates to immunogenic and immunoprotective compositions and methods for making and using homogenous synthetic Moraxella catarrhalis lipooligosaccharide (LOS)-based oligosaccharides, conjugates, and antibodies derived therefrom.is an important human mucosal pathogen that contributes to otitis media in infants and exacerbates conditions such as chronic obstructive pulmonary disease in the elderly. In view of the increased incidence of infection and increased virulence and antibiotic resistance found in modern clinical isolates, there is a need to identify and develop new therapies targeting this pathogen. Currently, there is no vaccine approved for human use.The lipooligosaccharides (LOS) of share a high degree of structural homology across the three known serotypes (A, B and C), including a common glucose core, indicating the potential for broad based coverage if an antibody response to a common epitope can be elicited.The present invention provides a synthetically produced vaccine approach targeting the LOS cores of . Native LOSs are composed of branched oligosaccharides anchored to the cell membrane via a KDO-lipid A linker. The KDO-lipid A glycolipid motif is found in many species of gram negative bacteria (Edebrink et al., 295:127-146, 1996).There is evidence that an antibody ...

Подробнее
25-04-2013 дата публикации

PROCESS FOR PERPARING FONDAPARINUX SODIUM AND INTERMEDIATES USEFUL IN THE SYNTHESIS THEREOF

Номер: US20130102764A1
Принадлежит: Reliable Biopharmaceutical Corporation

Processes for the synthesis of the Factor Xa anticoagulent Fondaparinux, and related compounds are described. Also described are protected pentasaccharide intermediates as well as efficient and scalable processes for the industrial scale production of Fondaparinux sodium by conversion of the protected pentasaccharide intermediates via a sequence of deprotection and sulfonation reactions. 114-. (canceled)18. The process of claim 17 , wherein deprotecting step (a) comprises treatment with a reagent selected from hydrazine claim 17 , hydrazine hydrate claim 17 , hydrazine acetate and RNH—NHwhere Ris aryl claim 17 , heteroaryl or alkyl.19. The process of claim 17 , wherein protecting step (b) comprises treatment with dihydropyran or a dihydropyran derivative and an acid selected from camphor sulfonic acid (CSA) claim 17 , hydrochloric acid (HCl) claim 17 , p-toluenesulfonic acid (pTsOH) and Lewis acids.25. The method of claim 24 , further comprising converting the fondaparinux-THP to fondaparinux sodium.27. The process of claim 26 , further comprising converting the resulting product to Fondaparinux sodium.33. The process of claim 32 , wherein the deprotecting step (a) comprises treatment with a reagent selected from hydrazine claim 32 , hydrazine hydrate claim 32 , hydrazine acetate and RNH—NHwhere Ris aryl claim 32 , heteroaryl or alkyl.34. The process of claim 33 , wherein the deprotecting step (a) comprises treatment with hydrazine.35. The process of claim 32 , wherein the protecting step (b) comprises treatment with dihydropyran or a dihydropyran derivative and an acid selected from camphor sulfonic acid (CSA) claim 32 , hydrochloric acid (HCl) claim 32 , p-toluenesulfonic acid (pTsOH) and Lewis acids.36. The process of claim 35 , wherein the protecting step (b) comprises treatment with dihydropyran and an acid selected from hydrochloric acid and p-toluenesulfonic acid.3743-. (canceled)44. A method of preparing an oligosaccharide comprising a β-glucosamine ...

Подробнее
02-05-2013 дата публикации

CRYPTIC GLYCAN MARKERS AND APPLICATIONS THEREOF

Номер: US20130108624A1
Принадлежит:

The present invention relates to a novel glycan marker of cancer and monoclonal antibodies against it. Furthermore, novel glycan markers and their use in the detection and monitoring of cancerous cells and cancer-associated or specific antibody signatures are described. 1. A glyco-epitope that is aberrantly expressed by tumor cells , including human melanoma (Trombelli , MM5) , prostate (PC3 , DU145 , LN-CAP) , breast (ZR75.1 , MDA-MB 468) , and ovarian cancer cell lines (PEA-1 , PEO-1 , SK-OV-3) and that is displayed by mannose-containing N-glycans of tumor cells and by high-mannose-cluster-carrier protein conjugates in carbohydrate microarrays.2. An antibody that specifically binds to the glyco-epitope of .3. The antibody of claim 2 , wherein said antibody is a mouse monoclonal claim 2 , mouse-human chimeric or humanized antibody claim 2 , or a functional fragment thereof.4. The antibody of claim 3 , that is an IgM antibody.5. The antibody of claim 3 , that is an IgG antibody.6. Monoclonal antibody TM 10 that specifically binds to the glyco-epitope of and that is produced by the hybridoma cell line TM10 and deposited with the ATCC on ______.7. Functional fragments of the monoclonal antibody of claim 6 , wherein the binding portion is selected from the group consisting of an Fab claim 6 , an F(ab′)2 fragment and an Fv fragment.8. The antibody of wherein the antibody is conjugated to a label that produces a detectable signal.9. The antibody of claim 8 , wherein the label is selected from the group consisting of a radiolabel claim 8 , an enzyme claim 8 , a chromophore and a fluorescer.10. Hybridoma cell line TM10 claim 8 , as deposited with the ATCC on ______.11. A method to detect cancerous cells or a portion thereof in a biological sample comprising: providing an antibody or binding portion thereof which recognizes the glyco-epitope of claim 8 , wherein the antibody is selected from claim 8 , claim 8 , or claim 8 , and wherein the antibody or binding portion ...

Подробнее
02-05-2013 дата публикации

Multidimensional Supramolecular Structures Essentially Made of Assembled I-Motif Tetramers

Номер: US20130109848A1

The present invention pertains to a supramolecular structure based on i-motif tetramers of C—X—Coligonucleotides, wherein m and n are integers comprised between 2 and 9, and X is a linker such as A, T, G, a modified deoxynucleotide or a diol spacer. These supramolecular structures can be dissociated, when necessary, by a mere pH change. The present invention also relates to methods for obtaining such a supramolecular structure. 1. (canceled)2. A supramolecular structure comprising N C—X—C(SEQ ID No: 1) oligonucleotides , wherein m and n are integers comprised between 2 and 7 , preferably between 3 and 7 , X is selected in the group consisting of A , T , G , a modified deoxynucleotide and a diol spacer , N an integer ≧8 and wherein each oligonucleotide is part of an i-motif tetramer.3. The supramolecular structure of claim 2 , wherein m≠n.4. The supramolecular structure of claim 2 , wherein (m claim 2 , n) is selected in the group of (4 claim 2 , 7) and (7 claim 2 , 4).5. The supramolecular structure according to claim 2 , wherein X=G.6. The supramolecular structure according to claim 2 , which comprises oligonucleotides having different sequences.7. The supramolecular structure according to claim 6 , comprising oligonucleotides of sequence C—X—C(SEQ ID No: 1) and terminator oligonucleotides.8. The supramolecular structure according to claim 7 , wherein at least part of said terminator oligonucleotides are covalently linked to a reactive group.9. The supramolecular structure according to claim 2 , wherein N≧50.10. A process for producing a supramolecular structure according to claim 2 , wherein said process comprises the following steps:{'sub': m', 'n, '(i) incubating a solution of oligonucleotides of sequence C—X—C(SEQ ID No: 1) wherein n and m are integers comprised between 2 and 9, preferably between 3 and 7, and X is selected in the group consisting of A, T, G, a modified deoxynucleotide and a diol spacer, in a buffer having a pH in the range 3 to 6, and'}(ii) ...

Подробнее
23-05-2013 дата публикации

METHOD FOR THE SYNTHESIS OF A TRISACCHARIDE

Номер: US20130131334A1

The present invention relates to an improved synthesis of a trisaccharide of the formula (1), novel intermediates used in the synthesis and the preparation of the intermediates. 119-. (canceled)21. The method according to claim 20 , characterized in that the catalytic hydrogenolysis is carried out in water claim 20 , in one or more C-Calcohols claim 20 , in a mixture water and one or more C-Calcohols claim 20 , or in a mixture of water claim 20 , one or more C-Calcohols and acetic acid claim 20 , in the presence of palladium on charcoal or palladium black.22. The method according to claim 20 , characterized in that O-(2 claim 20 ,3 claim 20 ,4-tri-O-benzyl-α-L-fucopyranosyl)-(1→2)-O-β-D-galactopyranosyl-(1→4)-D-glucose of the general formula 1 in hydrated form claim 20 , in crystalline water free form or in a mixture of hydrated and crystalline water free forms is applied.24. The compound according to claim 23 , wherein Rand R claim 23 , independently from each other claim 23 , means benzyl claim 23 , 4-methylbenzyl claim 23 , benzyloxycarbonyl claim 23 , naphthylmethyl claim 23 , 3-phenylbenzyl claim 23 , 4-chlorobenzyl claim 23 , 4-methoxybenzyl claim 23 , 3 claim 23 ,4-dimethoxybenzyl claim 23 , 2 claim 23 ,4 claim 23 ,6-trimethylbenzyl or 2 claim 23 ,3 claim 23 ,4 claim 23 ,5 claim 23 ,6-pentamethylbenzyl claim 23 , benzyl or 4-methylbenzyl and Ris H.27. The method according to claim 26 , characterized in that the acid catalyzed mild hydrolysis is conducted in aqueous acetic acid solution.28. The method according to claim 26 , characterized in that compounds of general formula 2 claim 26 , wherein R and R′ mean methyl claim 26 , one of the Rand Rgroups or both Rand Rgroups are 4-methylbenzyl and Ris H claim 26 , is applied.31. The method according to claim 30 , characterized in that the acid catalyzed mild hydrolysis is carried out in ethyl acetate/acetonitrile/water wherein the proportion of the ethyl acetate is more than 40 v/v %.32. The method according to ...

Подробнее
06-06-2013 дата публикации

GLYCOLIPID FOR TREATMENT OF ISCHEMIA REPERFUSION INJURY

Номер: US20130143828A1
Автор: Molteni Monica
Принадлежит: BLUEGREEN BIOTECH S.R.L.

The invention relates to a high molecular weight glycolipid characterized by the presence of rhamnose which has anti-inflammatory activity, particularly in inflammation triggered by ischemia and reperfusion. A further aspect of the invention is a process for preparation of said glycolipid from Cyanobacteria. 1. A glycolipid of general formula (I):{'br': None, 'sub': m', 'n, '(G)-(OCOR)\u2003\u2003(I)'}wherein,{'sub': 'm', '(G): is the total saccharidic fraction;'}{'sub': 'n', '(OCOR): is the total lipidic fraction;'}G is a saccharide;R is a linear hydrocarbon chain comprising from 12 to 24 carbon atoms;m is an integer from 50 to 150; andn is an integer from 2 to 5;wherein G, comprises at least one rhamnose unit.2. The glycolipid according to claim 1 , wherein G comprises at least one saccharide unit selected from the group consisting of galacturonic acid claim 1 , mannose claim 1 , galactose claim 1 , glucose claim 1 , glucosamine claim 1 , xylose and combinations thereof.3. The glycolipid according to claim 1 , wherein (G). comprises from 48 to 54% by weight of rhamnose (Rha) claim 1 , from 10 to 18% by weight of galacturonic acid (GalA) claim 1 , from 8 to 14% by weight of mannose (Man) claim 1 , from 8 to 14% by weight of galactose (Gal) claim 1 , from 2 to 9% by weight of glucose (Glc) claim 1 , from 2 to 6% by weight of glucosamine (GLcN) claim 1 , from 2 to 6% by weight of xylose (Xyl) with respect to the total saccharidic fraction (G)(100%).4. The glycolipid according to claim 1 , wherein R is a linear hydrocarbon chain comprising 18 carbon atoms [C] and wherein (OCO[C])is 45 to 65% by weight with respect to the total lipidic fraction (OCOR)(100%).5. (canceled)6. The glycolipid according to claim 4 , wherein R is a linear hydrocarbon chain comprising 16 carbon atoms [C] and wherein (OCO[C])is 20 to 45% by weight with respect to the total lipidic fraction (OCOR)(100%).7. (canceled)8. The glycolipid according to claim 1 , wherein when R is a linear hydrocarbon ...

Подробнее
20-06-2013 дата публикации

PROCESS FOR CONJUGATION OF NHS ESTERS WITH OLIGONUCLEOTIDES

Номер: US20130158243A1
Автор: Ball Robert William
Принадлежит: SIGMA-ALDRICH CO. LLC

The present invention provides processes for the conjugation of NHS esters to amino-modified oligonucleotides. The processes provide the amino-modified oligonucleotide on a solid support such that conjugation can be carried out under conditions that can accommodate a wide variety of NHS esters and oligonucleotides. 1. A process for conjugating a N-hydroxysuccinimide ester with an amino-modified oligonucleotide , the process comprising contacting the N-hydroxysuccinimide ester with the amino-modified oligonucleotide , wherein the amino-modified oligonucleotide is non-covalently bound to an ion exchange support.3. The process of claim 1 , wherein Rcomprises a fluorescent moiety claim 1 , a dye claim 1 , or a label.4. The process of claim 1 , wherein the amino-modified oligonucleotide comprises from about 5 to about 500 bases.5. The process of claim 1 , wherein the amino-modified oligonucleotide has a mass-average molecular weight of about 500 to about 100 claim 1 ,000 Da.6. The process of claim 1 , wherein the amino-modified oligonucleotide has a mass-average molecular weight of about 1 claim 1 ,500 to about 40 claim 1 ,000 Da.7. The process of claim 1 , wherein the amino group comprising the amino-modified oligonucleotide is free during conjugation.8. The process of claim 1 , wherein conjugation is conducted in a non-aqueous environment.9. The process of claim 1 , wherein the ion exchange support comprises a strong base exchanger.10. The process of claim 1 , wherein the ion exchange support comprises a quaternary or tertiary amine.11. A process for conjugating an N-hydroxysuccinimide ester with an amino-modified oligonucleotide claim 1 , the process comprising contacting the N-hydroxysuccinimide ester with the amino-modified oligonucleotide bound to a solid support claim 1 , wherein the process is conducted in a non-aqueous environment.13. The process of claim 11 , wherein Rcomprises a fluorescent moiety claim 11 , a dye claim 11 , or a label.14. The process of claim ...

Подробнее
27-06-2013 дата публикации

POLYMORPHS OF 2'-O-FUCOSYLLACTOSE AND PRODUCING THEREOF

Номер: US20130165406A1
Принадлежит: GLYCOM A/S

The present invention relates to novel polymorphs of the trisaccharide 2′-O-fucosyllactose (2-FL) of formula (1), methods for producing said polymorphs and their use in pharmaceutical or nutritional compositions. 1. Crystalline 2′-O-fucosyllactose polymorph II , characterized in that it displays X-ray powder diffraction reflections , based on a measurement using CuKα radiation , at 16.98±0.20 , 13.65±0.20 and 18.32±0.20 2Θ angles.2. The crystalline 2′-O-fucosyllactose polymorph II according to which is substantially pure.3. The crystalline 2′-O-fucosyllactose polymorph II according to which is substantially free from organic solvent and/or water.4. A method for producing crystalline 2′-O-fucosyllactose polymorph II according to claim 1 , characterized in that the crystallization is carried out from a solvent system comprising one or more C-Calcohols in the presence of seed crystals of crystalline 2′-O-fucosyllactose polymorph II according to .5. The method according to claim 4 , wherein the C-Calcohol is methanol and/or ethanol.6. The method according to claim 4 , wherein the solvent system further contains water.7. A method for producing crystalline 2′-O-fucosyllactose polymorph II according to claim 1 , characterized in that syrupy 2-FL claim 1 , solid 2-FL comprising amorphous 2-FL or any 2-FL polymorph(s) different to polymorph II claim 1 , or a mixture of amorphous 2-FL and any 2-FL polymorph(s) different to polymorph II is suspended in one or more less polar aprotic organic solvent.8. The method according to wherein the less polar aprotic organic solvent is an ester type solvent.9. 2′-O-Fucosyllactose polymorph I in polycrystalline or single crystal form claim 7 , characterized in that it displays X-ray powder diffraction reflections claim 7 , based on a measurement using CuKα radiation claim 7 , at 21.34±0.20 claim 7 , 20.92±0.20 and 18.37±0.20 2Θ angles.10. The crystalline 2′-O-fucosyllactose polymorph I according to in single crystal form claim 9 , ...

Подробнее
04-07-2013 дата публикации

COMPOSITIONS COMPRISING C5 AND C6 OLIGOSACCHARIDES

Номер: US20130172546A1
Принадлежит: RENMATIX, INC.

Compositions comprising C5 and C6 saccharides of varying degrees of polymerization and low levels of undesirable impurities, such as compounds containing sulfur, nitrogen, or metals, are disclosed. 1. A composition , comprising:at least one water-soluble C5 oligosaccharide hydrolysate;optionally, at least one water-soluble C5 monosaccharide hydrolysate; and 'wherein said elements are Al, As, B, Ba, Be, Ca, Cd, Co, Cr, Cu, Fe, K, Li, Mg, Mn, Mo, Na, Ni, P, Pb, S, Sb, Se, Si, Sn, Sr, Ti, Tl, V, and Zn.', 'less than about 3700 ppm in total by weight, based on total weight of said water-soluble C5 oligosaccharide hydrolysate and said water-soluble C5 monosaccharide hydrolysate in said composition, of elements;'}2. A composition of claim 1 ,wherein said water-soluble C5 oligosaccharide hydrolysate comprises a C6 oligosaccharide having a degree of polymerization of at least about 2 to about 28.3. A composition of claim 1 ,wherein said water-soluble C5 oligosaccharide hydrolysate comprises a C5 oligosaccharide having a degree of polymerization of at least about 2 to about 16.4. A composition of claim 1 ,wherein said water-soluble C5 oligosaccharide hydrolysate comprises a C5 oligosaccharide having a degree of polymerization of at least about 2 to about 10.5. A composition of claim 1 ,wherein said water-soluble C5 oligosaccharide hydrolysate comprises a C6 oligosaccharide having a degree of polymerization of at least about 2 to about 5.6. A composition of claim 1 , further comprising:at least one water-soluble C5 monosaccharide hydrolysate.7. A composition of claim 6 ,wherein said water-soluble C5 monosaccharide hydrolysate is xylose, arabinose, lyxose, ribose, or a mixture thereof.8. A composition of claim 1 ,wherein the ratio of the total weight of said water-soluble C5 oligosaccharide hydrolysate and said water-soluble C5 monosaccharide hydrolysate in said composition is greater than about 75:1.9. A composition of claim 1 , further comprising:less than about 10 ppm by ...

Подробнее
04-07-2013 дата публикации

COMPOSITIONS COMPRISING C5 AND C6 OLIGOSACCHARIDES

Номер: US20130172547A1
Принадлежит: RENMATIX, INC.

Compositions comprising C5 and C6 saccharides of varying degrees of polymerization and low levels of undesirable impurities, such as compounds containing sulfur, nitrogen, or metals, are disclosed. 1. A composition , comprising:at least one water-soluble C6 oligosaccharide hydrolysate;optionally, at least one water-soluble C6 monosaccharide hydrolysate; andless than about 5250 ppm in total by weight, based on total weight of said water-soluble C6 oligosaccharide hydrolysate and said water-soluble C6 monosaccharide hydrolysate in said composition, of elements;wherein said elements are Al, As, B, Ba, Be, Ca, Cd, Co, Cr, Cu, Fe, K, Li, Mg, Mn, Mo, Na, Ni, P, Pb, S, Sb, Se, Si, Sn, Sr, Ti, Tl, V, and Zn.2. A composition of claim 1 ,wherein said water-soluble C6 oligosaccharide hydrolysate comprises a C6 oligosaccharide having a degree of polymerization of about 2 to about 15.3. A composition of claim 1 ,wherein said water-soluble C6 oligosaccharide hydrolysate comprises a C6 oligosaccharide having a degree of polymerization of about 2 to about 13.4. A composition of claim 1 ,wherein said water-soluble C6 oligosaccharide hydrolysate comprises a C6 oligosaccharide having a degree of polymerization of about 2 to about 10.5. A composition of claim 1 ,wherein said water-soluble C6 oligosaccharide hydrolysate comprises a C6 oligosaccharide having a degree of polymerization of about 2 to about 6.6. A composition of claim 1 , further comprising:at least one water-soluble C6 monosaccharide hydrolysate.7. A composition of claim 6 ,wherein said water-soluble C6 monosaccharide hydrolysate is glucose, galactose, mannose, fructose, or a mixture thereof.8. A composition of claim 1 ,wherein the ratio of the total weight of said water-soluble C6 oligosaccharide hydrolysate and said water-soluble C6 monosaccharide hydrolysate to said elements is greater than about 45:1.9. A composition of claim 1 , further comprising:less than about 10 ppm by weight, based on total weight of said water- ...

Подробнее
11-07-2013 дата публикации

USE OF MODIFIED OLIGO-B-(1,3)-GLUCANES FOR TREATING DISEASES OF THE IMMUNE SYSTEM OLIGO-B-(1,3V-GLUCANE-(1,3)-MANNOSE, OLIGO-B-(1,3)-GLUCANE-(1,3)-MANNITOL AND DERIVATIVES THEREOF, METHODS FOR PREPARING THE SAME AND DRUGS CONTAINING THEM

Номер: US20130178616A1
Принадлежит: ASE & BIO.

The present invention relates to the use of at least one compound of formula (III), (IV), (V) or (VI), in which p is an integer from 0 to 9; and R2 represents hydrogen, allyl, methylnaphthyl, benzyl, paramethoxybenzyl, or halogenoacetyl, for the preparation of a medicament for treating diseases such as tumors, cancer, viral disease, bacterial disease, fungal disease, disease of the immune system, auto-immune disease or disease linked to a deficiency in immunostimulation, in human beings and warm-blooded animals. The invention also relates to new products having a mannose or mannitol termination as well as a method for preparing them. 2. The compound according to claim 1 , wherein p is an integer from 0 to 6.3. The compound according to claim 1 , wherein p is equal to 2 claim 1 , 3 or 4.4. The compound according to claim 1 , wherein the halogenoacetyl group of R2 is selected from the group consisting of chloroacetyl claim 1 , bromoacetyl and iodoacetyl.5. The compound according to claim 1 , wherein the trialkylsilyl group of R3 claim 1 , R4 claim 1 , R3′ claim 1 , R4′ and R5 is selected from the group consisting of triethylsilyl claim 1 , tri-iso-propylsilyl and tertiobutyldimethylsilyl.6. The compound according to claim 1 , wherein the ester group of R3 claim 1 , R4 claim 1 , R3′ and R4′ is selected from the group consisting of acetyl claim 1 , chloroacetyl claim 1 , benzoyl claim 1 , and pivaloyl.7. The compound according to claim 1 , wherein R5 represents a levulinoyl group.8. The compound according to claim 1 , wherein the ester group of R7 is selected from the group consisting of acetyl claim 1 , benzoyl claim 1 , and pivaloyl.9. The compound according to claim 1 , wherein the ester group of R7 represents a benzoyl group.10. The compound according to claim 1 , wherein R8 represents Bn. This application is a Divisional of U.S. application Ser. No. 12/520,612, filed Mar. 12, 2010, which is a 371 application of PCT/FR2007/052595, filed Dec. 20, 2007, all of said ...

Подробнее
18-07-2013 дата публикации

NOVEL SYNTHESIS OF 5-DEOXY-5'-FLUOROCYTIDINE COMPOUNDS

Номер: US20130184451A1
Принадлежит: PharmaEssentia Corp.

This invention relates to a process of synthesizing a β-nucleoside compound of formula (I): 2. The process of claim 1 , wherein the base is selected from the group consisting of pyridine claim 1 , immidazole claim 1 , ammonium claim 1 , monoalkylamine claim 1 , dialkylamine claim 1 , trialkylamine claim 1 , sodium carbonate claim 1 , and potassium carbonate.3. The process of claim 1 , wherein the solvent is acetone claim 1 , acetonitrile claim 1 , dimethylformamide claim 1 , ethyl acetate claim 1 , 1 claim 1 ,2-dichloroethane (DCE) claim 1 , dimethylacetamide (DMAC) claim 1 , dimethylsulfoxide (DMSO) claim 1 , tetrahydrofuran claim 1 , isopropyl acohol claim 1 , acetonitrile claim 1 , or nitromethane claim 1 , or a mixture of ACN/HO or acetone/HO.4. The process of claim 1 , wherein X is Cl claim 1 , 4-nitrophenoxy claim 1 , or N-succinimidyloxy.5. The process of claim 1 , wherein Ris alkyl.6. The process of claim 5 , wherein Ris n-pentyl.7. The process of claim 1 , wherein the base is pyridine or immidazole.8. The process of claim 6 , wherein X is Cl claim 6 , 4-nitrophenoxy claim 6 , or N-succinimidyloxy.9. The process of claim 8 , wherein the base is pyridine or immidazole.10. The process of claim 9 , wherein the solvent is acetone claim 9 , acetonitrile claim 9 , dimethylformamide claim 9 , ethyl acetate claim 9 , 1 claim 9 ,2-dichloroethane (DCE) claim 9 , dimethylacetamide (DMAC) claim 9 , dimethylsulfoxide (DMSO) claim 9 , tetrahydrofuran claim 9 , isopropyl acohol claim 9 , acetonitrile claim 9 , or nitromethane claim 9 , or a mixture of ACN/HO or acetone/HO.11. The process of claim 10 , wherein the solvent is DMF claim 10 , DMSO claim 10 , or DMAC.12. The process of claim 11 , wherein X is Cl.13. The process of claim 12 , where the base is pyridine.14. The process of claim 13 , wherein the reaction is carried out at a temperature of 50-100° C.15. The process of claim 14 , wherein the reaction is carried out at a temperature of 65-80° C.16. The process of ...

Подробнее
01-08-2013 дата публикации

MODIFIED NUCLEOTIDES

Номер: US20130197209A1
Принадлежит: ILLUMINA CAMBRIDGE LIMITED

The invention provides modified nucleotide or nucleoside molecule comprising a purine or pyrimidine base and a ribose or deoxyribose sugar moiety having a removable 3′-OH blocking group covalently attached thereto, such that the 3′ carbon atom has attached a group of the structure —O—Z wherein Z is any of —C(R′)2-O—R″, —C(R′)2-N(R″)2, —C(R′)2-N(H)R″, —C(R′)2-S—R″ and —C(R′)2-F, wherein each R″ is or is part of a removable protecting group; each R′ is independently a hydrogen atom, an alkyl, substituted alkyl, arylalkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclic, acyl, cyano, alkoxy, aryloxy, heteroaryloxy or amido group, or a detectable label attached through a linking group; or (R′)2 represents an alkylidene group of formula ═C(R′″)2 wherein each R′″ may be the same or different and is selected from the group comprising hydrogen and halogen atoms and alkyl groups; and wherein said molecule may be reacted to yield an intermediate in which each R″ is exchanged for H or, where Z is —C(R′) 2-F, the F is exchanged for OH, SH or NH2, preferably OH, which intermediate dissociates under aqueous conditions to afford a molecule with a free 3′OH; with the proviso that where Z is —C(R′)2-S—R″, both R′ groups are not H. 118-. (canceled)19. A method of converting a compound of formula R—O-allyl , RN(allyl) , RNH(allyl) , RN(allyl)or R—S-allyl to a corresponding compound in which the allyl group is removed and replaced by hydrogen , said method comprising the steps of reacting a compound of formula R—O-allyl , RN(allyl) , RNH(allyl) , RN(allyl)or R—S-allyl in aqueous solution with a transition metal comprising a transition metal and one or more bands selected from the group comprising water-soluble phosphine and water-soluble nitrogen-containing phosphine ligands , wherein the or each R is a water-soluble biological molecule , which is part of a nucleoside , a nucleotide or polynucleotide molecule , wherein said nucleoside , nucleotide or polynucleotide further comprises a ...

Подробнее
01-08-2013 дата публикации

Low Temperature Chlorination of Carbohydrates

Номер: US20130197213A1

Disclosed is a method of chlorinating a carbohydrate or derivative thereof, for example, a sucrose-6-ester at the 4,1′, and 6′ positions, with irreversible removal of HCl formed during the reaction to form the chlorinated carbohydrate or derivative thereof, for example, a 4,1′,6′-trichloro-4,1′,6′-trideoxy-6-O-ester of galactosucrose (TGS-6E). The irreversible removal of HCl can be carried out by an irreversible physical process and/or an irreversible chemical process. Sucralose, an artificial sweetener, can be prepared by deesterification of the TGS-6E. The chlorination reaction takes place at low temperatures and the desired chlorinated product is obtained in high yields and in high purities. 1. A method for chlorinating a carbohydrate or a derivative thereof comprising reacting the carbohydrate or derivative thereof with a chlorinating agent and irreversibly removing during chlorination the hydrogen chloride produced by the reaction of the chlorinating agent with the carbohydrate or derivative thereof.2. The method of claim 1 , wherein the carbohydrate or derivative thereof is a sugar or derivative thereof.3. The method of claim 2 , wherein the sugar derivative is a sugar ester.4. The method of claim 3 , wherein the sugar ester is a sucrose-6-ester.5. The method of claim 4 , wherein the chlorinated product obtained is 4 claim 4 ,1′ claim 4 ,6′-trichloro-4 claim 4 ,1′ claim 4 ,6′-trideoxy-6-O-ester of galactosucrose (TGS-6E).6. The method of claim 1 , wherein the chlorinating agent is an acid chloride.7. The method of claim 6 , wherein the chlorinating agent is a Vilsmeier Reagent having the formula: [XYC═NR]Cl claim 6 , wherein X is hydrogen claim 6 , aryl claim 6 , or alkyl claim 6 , wherein the aryl or alkyl is optionally substituted with a halogen claim 6 , alkoxy claim 6 , thioalkoxy claim 6 , amido claim 6 , or cyano; Y is a leaving group; and R is hydrogen or alkyl which is optionally substituted with halogen claim 6 , alkoxy claim 6 , thioalkoxy claim 6 , ...

Подробнее
15-08-2013 дата публикации

COMPOSITION SUPPRESSING MATRIX-METALLOPROTEINASE ACTIVITY

Номер: US20130211059A1
Принадлежит: UNIVERSITY OF MIYAZAKI

An object of the present invention is to provide a composition having the effect of suppressing matrix metalloproteinase activity. Specifically, the present invention relates to a composition suppressing matrix metalloproteinase activity containing a glycolysis inhibitor as an active ingredient. 1. A composition suppressing matrix metalloproteinase activity , containing , as an active ingredient , a glycolysis inhibitor selected from the group consisting of 2-deoxyglucose , a derivative and a salt thereof.2. (canceled)3. The composition suppressing matrix metalloproteinase activity of claim 1 , wherein the matrix metalloproteinase is a matrix metalloproteinase in macrophages.4. The composition suppressing matrix metalloproteinase activity of claim 1 , wherein the matrix metalloproteinase is matrix metalloproteinase-9.5. A therapeutic agent for matrix metalloproteinase-activation-related diseases containing claim 1 , as an active ingredient claim 1 , the composition suppressing matrix metalloproteinase activity of .6. The therapeutic agent for matrix metalloproteinase-activation-related diseases of claim 5 , wherein the matrix metalloproteinase-activation-related diseases are atherosclerosis or abdominal aortic aneurysm.7. A composition regulating expression of an atherosclerosis-related or an abdominal aortic aneurysm-related gene containing claim 5 , as an active ingredient claim 5 , a glycolysis inhibitor selected from the group consisting of 2-deoxyglucose claim 5 , a derivative and a salt thereof.8. The composition regulating expression of the atherosclerosis-related or the abdominal aortic aneurysm-related gene of claim 7 , wherein the atherosclerosis-related or the abdominal aortic aneurysm-related gene is selected from the group consisting of a gene encoding a chemokine claim 7 , a gene encoding an inflammatory cytokine and an SIRT-1 gene.9. The composition regulating expression of the atherosclerosis-related or the abdominal aortic aneurysm-related gene of ...

Подробнее
19-09-2013 дата публикации

GLYCOCONJUGATES AND THEIR USE AS POTENTIAL VACCINES AGAINST INFECTION BY SHIGELLA FLEXNERI

Номер: US20130243751A1
Принадлежит:

A conjugate molecule comprising an oligo- or polysaccharide covalently bound to a carrier and its use as potential vaccine against infection by 1. A conjugate molecule comprising an oligo- or polysaccharide selected from the group consisting of:{'sub': x', 'y, '(X)-{B(E)C}-(Y)'}{'sub': x', 'y, '(X)-{(E)CD}-*Y)'}{'sub': x', 'y, '(X)-{AB(E)C}-(Y)'}{'sub': x', 'y, '(X)-{B(E)CD}-(Y)'}{'sub': x', 'y, '(X)-{(E)CDA}-(Y)'}{'sub': x', 'y, '(X)-{DAB(E)C}n-(Y)'}{'sub': x', 'y, '(X)-{B(E)CDA}n-(Y)'}{'sub': x', 'y, '(X)-{(E)CDAB}n-(Y)'}{'sub': x', 'y, '(X)-{AB(E)CD}n-(Y)'}{'sub': x', 'y, '(X)-{DAB(E)CD}-(Y)'}{'sub': x', 'y, '(X)-{B(E)CDAB(E)C}-(Y)'}wherein:A is an alphaLRhap-(1,2) residueB is an alphaLRhap-(1,3) residueC is an alphaLRhap-(1,3) residueE is an alphaDGlcp-(1,4) residueD is a betaDGlcNAcp-(1,2) residuex and y are independently selected among 0 and 1X and Y are independently selected among A, B, C, D, E, AB, B(E), (E)C, CD, DA, AB(E), B(E)C, (E)CD, CDA, AB(E)C, B(E)CD, (E)CDA, CDAB, DAB(E) and wherein n is an integer comprised between 1 and 10 covalently bound to a carrier.2. A molecule according to wherein n is comprised between 2 and 6.3. A molecule according to wherein the carrier is selected among a protein or a peptide comprising at least one T-cell epitope claim 1 , or a derivative thereof.4. A molecule according to claim 3 , wherein the carrier is the peptide PADRE.5. A molecule according to claim 3 , wherein the carrier is the tetanus toxoid.6. A molecule according to claim 1 , wherein the carrier is biotin.7. A molecule according to claim 1 , wherein the saccharide is directly bound to the carrier.8. A molecule according to claim 1 , wherein the saccharide is bound to the carrier via a spacer.9. A molecule according to claim 1 , wherein the saccharide to carrier ratio is comprised between 1:1 and 30:1.10. A molecule according to claim 1 , wherein the saccharide is selected among the tetrasaccharides and pentasaccharides and their oligomers.11. A molecule ...

Подробнее
19-09-2013 дата публикации

INDUCED INTERNALIZATION OF SURFACE RECEPTORS

Номер: US20130243769A1

Disclosed is a hetero-bifunctional ligand for use in inducing internalization of a target receptor. The hetero-bifunctional ligand includes a target receptor-binding agent that specifically binds the target receptor linked to an internalizing receptor-binding agent that specifically binds to an internalizing receptor, where the two binding agents are non-identical. Also disclosed is a method of inducing the internalization of a target receptor on a cell. The method includes contacting a cell with a hetero-bifunctional ligand, where binding of the hetero-bifunctional ligand induces internalization of a target receptor of the cell. Also disclosed is a method of treating a disease or condition associated with a target receptor using the disclosed hetero-bifunctional ligand and pharmaceutical compositions including a hetero-bifunctional ligand. 1. A hetero-bifunctional ligand for use in inducing internalization of a target receptor , comprising:a target receptor-binding agent that specifically binds the target receptor;a heterologous internalizing receptor-binding agent that specifically binds to an internalizing receptor, wherein binding of the hetero-bifunctional ligand to the internalizing receptor on a cell induces internalization of the internalizing receptor and wherein the target receptor-binding agent and the internalizing receptor-binding agent are not identical; anda linker linking the target receptor-binding agent to the internalizing receptor-binding agent, wherein the linker has a length sufficient to allow the hetero-bifunctional ligand to bind to the target receptor and the internalizing receptor on the cell.2. The hetero-bifunctional ligand of claim 1 , wherein the internalizing receptor-binding agent and the target receptor-binding agent do not specifically bind the same receptor.3. The hetero-bifunctional ligand of claim 1 , wherein the linker is a heterologous linker.4. The hetero-bifunctional ligand of claim 1 , wherein the target receptor-binding ...

Подробнее
19-09-2013 дата публикации

METHOD FOR PRODUCING L-FUCOSE

Номер: US20130245250A1
Принадлежит: GLYCOM A/S

Method for producing L-fucose includes in a first aspect, a method for the preparation of L-fucose, wherein L-fucose precursors are produced from pectin and L-fucose is produced from the L-fucose precursors; in a second aspect, a method for the preparation of L-fucose from D-galacturonic acid or a salt thereof, wherein L-fucose precursors are produced from D-galacturonic acid of a salt thereof, and L-fucose is produced from the L-fucose precursors; and an L-fucose precursor as shown in Formula A, wherein R is a linear or branched chain saturated hydrocarbon group with 1-6 carbon atoms, such as methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, n-hexyl, etc., preferably a methyl group. 1. A method of producing L-fucose from D-galacturonic acid or a salt thereof , comprising:a) producing at least one L-fucose precursor from D-galacturonic acid or a salt thereof, andb) producing L-fucose from the at least one L-fucose precursor.2. The method according to claim 1 , comprising:a) producing L-galactonic acid, a salt thereof or L-galactonic acid γ-lactone from D-galacturonic acid or a salt thereof, andb) producing L-fucose from L-galactonic acid, a salt thereof, or L-galactonic acid γ-lactone.3. The method according to claim 2 , wherein the production of L-galactonic acid claim 2 , a salt thereof or its γ-lactone from D-galacturonic acid or a salt thereof comprises the treatment of D-galacturonic acid or a D-galacturonate salt with NaBH.4. The method according to claim 1 , comprising:a) producing 6-bromo-6-deoxy-L-galactonic acid alkyl ester or 6-bromo-6-deoxy-L-galactonolactone from D-galacturonic acid or a salt thereof, andb) producing L-fucose from 6-bromo-6-deoxy-L-galactonic acid alkyl ester or 6-bromo-6-deoxy-L-galactonolactone.5. The method according to claim 4 , wherein a) comprises producing L-galactonic acid claim 4 , a salt thereof or its γ-lactone from D-galacturonic acid or a salt thereof and producing 6-bromo-6-deoxy-L-galactonic acid ...

Подробнее
03-10-2013 дата публикации

STEM CELL SUSPENSION

Номер: US20130260461A1
Принадлежит:

The present invention provides a mammalian stem cell suspension containing mammalian stem cells and at least one polysaccharide such as trehalose, and the like; a mammalian stem cell aggregation inhibitor containing polysaccharide such as trehalose, and the like; a method of suppressing aggregation of mammalian stem cells, containing suspending the mammalian stem cells in an aqueous physiological solution containing polysaccharide; an inhibitor of a decrease in the survival rate of mammalian stem cells containing polysaccharide such as trehalose and the like; a method of suppressing a decrease in the survival rate of mammalian stem cells, containing suspending the mammalian stem cells in an aqueous physiological solution containing polysaccharides, and the like. 110-. (canceled)11. A mammalian stem cell aggregation inhibitor comprising at least one polysaccharide selected from the group consisting of trehalose , hydroxyethylstarch and dextran.12. The mammalian stem cell aggregation inhibitor according to claim 11 , wherein the stem cell is an adhesive stem cell.13. The mammalian stem cell aggregation inhibitor according to claim 12 , wherein the adhesive stem cell is a mesenchymal stem cell or a pluripotent stem cell.14. The mammalian stem cell aggregation inhibitor according to claim 11 , wherein the polysaccharide is trehalose claim 11 , which inhibitor is used such that the concentration of trehalose in a mammalian stem cell suspension is within the range of 4.53-362.4 mg/ml.15. The mammalian stem cell aggregation inhibitor according to claim 11 , wherein the polysaccharide is dextran claim 11 , which inhibitor is used such that the concentration of dextran is within the range of 30-100 mg/ml.16. A method of suppressing aggregation of mammalian stem cells claim 11 , comprising suspending the mammalian stem cells in an aqueous physiological solution containing at least one polysaccharide selected from the group consisting of trehalose claim 11 , hydroxyethylstarch ...

Подробнее
03-10-2013 дата публикации

FUNCTIONALIZED 3-ALKYNYL PYRAZOLOPYRIMIDINE ANALOGUES AS UNIVERSAL BASES AND METHODS OF USE

Номер: US20130261014A1
Принадлежит:

3-alkynyl inosine analogs and their uses as universal bases are provided. The inosine analogues can be incorporated into nucleic acid primers and probes. They do not significantly destabilize nucleic acid duplexes. As a result, the novel nucleic acid primers and probes incorporating the inosine analogues can be used in a variety of methods. The analogs function unexpectedly well as universal bases. Not only do they stabilize duplexes substantially more than hypoxanthine opposite A, C, T, and G but they are also recognized in primers by polymerases, allowing efficient amplification. 2. The method of claim 1 , wherein the mismatched duplex has substantially the same stability as a corresponding duplex with a natural base in place of 3-alkynyl-1H-pyrazolo[3 claim 1 ,4-d]pyrimidin-4(5H)-one analogue.3. The method of claim 1 , wherein the mismatched base is A claim 1 , T or C.4. The method of wherein the mismatched base is G.5. The method of wherein the 3-alkynyl-1H-pyrazolo[3 claim 1 ,4-d]pyrimidin-4(5H)-one analogue is substituted with pyrene.6. A method for monitoring of polynucleotide amplification of a set of target nucleic acid sequences claim 1 , comprising:(a) providing a mixture comprising a sample containing the target nucleic acid sequences, one or more than one oligonucleotide primers substantially complementary to a portion of the target nucleic acid sequences, a polymerizing enzyme, nucleotide substrates, and a detectable nucleic acid oligomer probe of between 5 and 100 bases,wherein said detectable nucleic acid oligomer probe has a backbone component selected from the group consisting of a sugar phosphate backbone, a modified sugar phosphate backbone, a locked nucleic acid backbone, a peptidic backbone, or a variant thereof,wherein said nucleic acid oligomer probe has a sequence substantially complementary to a probe region of the target nucleic acid sequence,wherein said nucleic acid oligomer probe comprises a fluorophore,wherein at least one of said ...

Подробнее
03-10-2013 дата публикации

MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS

Номер: US20130261077A1
Принадлежит: VERTEX PHARMACEUTICALS INCORPORATED

The present invention relates to compounds useful for the treatment or prevention of bacteria infections. These compounds have formula I: 2. The compound of claim 1 , wherein{'sub': 8', '8', '2', 'm', '8', '8', '8', '2', '8', '2', '8', '8', '2', '8', '1', '6', '1', '6', '1', '6', '1', '6', 'n', '1-6', '8', '1-6', '8', '1-6', '1', '6, 'sup': '10', 'Y is absent, or is —NR, —O—, —S—, —C(O)—, —C(R)(OH)—, —C(O)N(R)(CH)—, —N(R)C(O)O—, —OC(O)NR—, —NRSO—, —NR—C(O)—, —SO—, —NRC(O)NR—, —S(O)—, —SONR, —(C-C)alkyl-, —(C-C)alkenyl-, —(C-C)alkynyl-, —(O—(C-Calkyl))-, —O—(Calkyl)NRC(O)—, —O—(Calkyl)C(O)NR, —O—(Calkyl)-C(O)—, or —((C-C)alkyl)-O—;'}{'sub': 3A', '3B', '10', '3', '10', '2', '2', 'n', '4', '2', 'n', '4', '2', 'n', '4', '2', '4', '4', '2', '4', '4', '2', '4', '4', '2', '4', '4', '2', '4', '4', '4', '2', '4', '4', '4', '2', '4', '2, 'each Rand Ris independently —OH, —CN, halogen, —C(R), —C(R)OH, —(CH)OR, —(CH)C(O)OR, —(CH)N(R), —C(O)OR, —C(O)N(R), —N(R)C(O)(R), —OC(O)NHR, —NHC(O)OR, —NHSOR, —NH—C(O)R, —SO—R, —NHC(O)NHR, —S(O)R, —SONHR, —SR, —P(O)(OR), or —P(O)(R); and'}{'sub': 4A', '10', '3', '10', '2', '2', 'n', '4', '2', 'n', '4', '2', 'n', '4', '2', '4', '4', '2', '4', '4', '2', '4', '4', '2', '4', '4', '2', '4', '4', '4', '2', '4', '4', '4', '2', '4', '2, 'Ris —OH, —CN, halogen, —C(R), —C(R)OH, —(CH)OR, —(CH)C(O)OR, —(CH)N(R), —C(O)OR, —C(O)N(R), —N(R)C(O)(R), —OC(O)NHR, —NHC(O)OR, —NHSOR, —NH—C(O)R, —SO—R, —NHC(O)NHR, —S(O)R, —SONHR, —SR, —P(O)(OR), —P(O)(R); and'}{'sup': '7', 'Ris H or mannosyl.'}3. The compound of claim 1 , wherein:X is —OH;{'sub': 8', '2', '1', '6', '1', '6', '1', '6', '1', '6', 'n', '1-6', '8', '1-6', '8', '1-6', '1', '6, 'sup': '10', 'Y is absent, or is —NR, —O—, —S—, —C(O)—, —C(R)(OH)—, —SO—, —S(O)—, —(C-C)alkyl, —(C-C)alkenyl, —(C-C)alkynyl, —(O—(C-Calkyl))-, —O(Calkyl)N—RC(O)—, —O—(Calkyl)-C(O)NR, —O—(Calkyl)C(O)—, or —((C-C)alkyl)-O—;'}{'sub': 2', '6-10', '6-10', '1', '6', '2', '6-10', '6-10', '1', '6, 'Ris Caryl, (Caryl)-(C-Calkyl)-, or 5- ...

Подробнее
03-10-2013 дата публикации

EFFICIENT AND SCALABLE PROCESS FOR THE MANUFACTURE OF FONDAPARINUX SODIUM

Номер: US20130261291A1
Принадлежит: Reliable Biopharmaceutical Corporation

The present invention relates to a process for the synthesis of the Factor Xa anticoagulent Fondaparinux and related compounds. The invention relates, in addition, to efficient and scalable processes for the synthesis of various intermediates useful in the synthesis of Fondaparinux and related compounds. 118-. (canceled)20. The process of claim 19 , further comprising converting the monosaccharide AMod3 to Fondaparinux sodium. This application claims the benefit of U.S. Provisional Patent Application No. 61/256,855, filed Oct. 30, 2009, which is hereby incorporated by reference. This application incorporates by reference U.S. Provisional Application Ser. No. 61/230,557, filed Jul. 31, 2009 and U.S. patent application Ser. No. 12/847,719, filed Jul. 30, 2010.The present invention relates to a process for the synthesis of the Factor Xa anticoagulent Fondaparinux and related compounds. The invention relates, in addition, to efficient and scalable processes for the synthesis of various intermediates useful in the synthesis of Fondaparinux and related compounds.In U.S. Pat. No. 7,468,358, Fondaparinux sodium is described as the “only anticoagulant thought to be completely free of risk from HIT-2 induction.” The biochemical and pharmacologic rationale for the development of a heparin pentasaccharide in 86(1). 1-36, 1997 by Walenga et al. cited the recently approved synthetic pentasaccharide Factor Xa inhibitor Fondaparinux sodium. Fondaparinux has also been described in Walenga et al., , Vol. 11, 397-407, 2002 and Bauer, & , Vol. 17, No. 1, 89-104, 2004.Fondaparinux sodium is a linear octasulfated pentasaccharide (oligosaccharide with five monosaccharide units) molecule having five sulfate esters on oxygen (O-sulfated moieties) and three sulfates on a nitrogen (N-sulfated moieties). In addition, Fondaparinux contains five hydroxyl groups in the molecule that are not sulfated and two sodium carboxylates. Out of five saccharides, there are three glucosamine derivatives and ...

Подробнее
17-10-2013 дата публикации

ACTIVE INGREDIENT WITH CUTANEOUS APPLICATION OBTAINED FROM METSCHNIKOWIA AGAVES AND USES FOR IMPROVING THE STATE OF THE SKIN

Номер: US20130274221A1
Автор: PAUFIQUE Jean

An active ingredient with cutaneous application obtained from as well as its use for preventing and/or combating ageing of the skin and its visible manifestations, and cosmetic compositions including this active ingredient and to a cosmetic process for skin care. 1Metschnikowia agaves.. An active ingredient intended for use in a composition with cutaneous application , obtained from2. The active ingredient according to claim 1 , comprising carbohydrates.3. The active ingredient according to claim 1 , comprising oligosaccharides.4. The active ingredient according claim 3 , wherein the oligosaccharides have a degree of polymerization of between 2 and 42.5. The active ingredient according to claim3 claim 3 , wherein the oligosaccharides are α-glucan oligosaccharides and β-glucan oligosaccharides and have a degree of polymerization of between 2 and 17.6. The active ingredient according to claim 3 , wherein the oligosaccharides are at least 63% by weight of total sugars present in the active ingredient.7Metschnikowia agaves. The active ingredient according to claim 1 , wherein the active ingredient is a hydrolyzate.8. The active ingredient according to claim 1 , wherein the active ingredient is in a liquid form claim 1 , and the active ingredient has:a level of dry materials of between 35 and 50 g/l, anda total sugar level of between 16 and 24 g/l.9. A method for improving the state of the skin comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'cutaneously applying to the skin of a subject in need thereof, an effective amount of a cosmetic composition comprising said active ingredient according to , wherein said active ingredient and/or said composition improve the state of skin.'}10. The method according to claim 9 , wherein said active ingredient and/or said composition improves the state of skin by combating the ageing of the skin.11. The method according to claim 9 , wherein said active ingredient and/or said composition improves the state of skin by ...

Подробнее
24-10-2013 дата публикации

METHODS FOR THE PREPARATION OF DIASTEROMERICALLY PURE PHOSPHORAMIDATE PRODRUGS

Номер: US20130281686A1
Принадлежит: Gilead Sciences, Inc.

Provided are methods and intermediates for preparing diastereomerically pure phosphoramidate prodrugs of nucleosides of Formulas Ia and Ib: 8. The method of wherein Ris H claim 1 , halogen claim 1 , optionally substituted (C-C)alkyl claim 1 , optionally substituted (C-C)alkenyl or optionally substituted (C-C)alkynyl.9. The method of wherein Ris H claim 8 , CHor F.10. The method of wherein each R claim 1 , Rand Ris H.11. The method of wherein one of Ror Ris H and the other of Ror Ris optionally substituted (C-C)alkyl.12. The method of wherein Ris optionally substituted (C-C)alkyl.13. The method of wherein Ris NRRor OR.14. The method of wherein Ris H or NRR.15. The method of wherein when Ror Ris ORor NRRthen each Rand Rof said ORor NRRis H.16. The method of wherein Ris NHand Ris H.17. The method of wherein Ris optionally substituted (C-C)aryl.19. The method of wherein the compound of Formula VIII is dissolved in an ether solvent and the crystallization is induced by addition of a C-Chydrocarbon.20. The method of wherein the compound of Formula VIII is dissolved in diethyl ether or methyl-t-butyl ether and crystallization is induced by the addition of hexane.21. The method of wherein the compound of Formula VIII is dissolved in diethyl ether and crystallization is induced by the addition of hexane.24. The method of wherein the compound of Formula VIII is dissolved in an ether solvent and the crystallization is induced by addition of a C-Chydrocarbon.25. The method of wherein the compound of Formula VIII is dissolved in diethyl ether or methyl-t-butyl ether and crystallization is induced by the addition of hexane.26. The method of wherein the compound of Formula VIII is dissolved in diethyl ether and crystallization is induced by the addition of hexane.29. The method of wherein Ris H and one of Ror Ris H.30. The method of wherein Ris optionally substituted (C-C)alkyl and Ris optionally substituted (C-C)aryl.31. The method of wherein Ris optionally substituted phenyl.32. ...

Подробнее
14-11-2013 дата публикации

MIXED SUPER CRITICAL FLUID HYDROLYSIS AND ALCOHOLYSIS OF CELLULOSE TO FORM GLUCOSE AND GLUCOSE DERIVATIVES

Номер: US20130303742A1
Принадлежит:

The present invention relates to a process for generating glucose and glucose derivatives from the direct contacting of cellulose, hemicelluloses and/or polysaccharides with a mixed super critical fluid system of alcohol and water whereby the partial pressure of the system provides for both alcoholysis and hydrolysis of the material to generate primarily glucose, and glucose derivatives. 1. A method for making a hexose , a pentose , an alkyl glucoside , or an alkyl pentoside , the method comprising:(a) (i) combining a feedstock with an alcohol and water,wherein the feedstock comprises a cellulosic material, a protein, or both a cellulosic material and a protein; or(ii) combining a feedstock with an alcohol and water,wherein the feedstock comprises a cellulosic material, a hemicellulose-comprising material, or both a cellulosic material and a hemicellulose-comprising material; and(b) reacting the feedstock and the alcohol and water at a temperature in the range of between about 140° C. to 350° C., and at a pressure in a range of between about 500 psig to 3200 psig to cleave the cellulosic material to generate a product comprising a hexose, a pentose, an alkyl glucoside, or an alkyl pentoside.2. The method of claim 1 , wherein the feedstock comprises at least about 10 wt % cellulosic material based on the dry weight of the feedstock.3. The method of claim 1 , wherein the feedstock comprises at least about 10 wt % proteins based on the dry weight of the feedstock.4. The method of claim 1 , wherein the water content of the combination of (a)(ii) before the reaction of (b) is from about 30 wt % to about 300 wt % of the dry weight of the feedstock.5. The method according to claim 1 , wherein said feedstock comprises a rice husk claim 1 , a rice bran claim 1 , a corn stover claim 1 , a corn cob claim 1 , a sugar cane bagasse claim 1 , a palm fiber claim 1 , a palm kernel cake claim 1 , a wood pulp claim 1 , a pine tree material claim 1 , a fir tree material claim 1 , a ...

Подробнее
19-12-2013 дата публикации

METHODS FOR PURIFYING MONOSACCHARIDE MIXTURES CONTAINING IONIC IMPURITIES

Номер: US20130338086A1
Принадлежит: Aptalis Pharma Canada Inc.

Disclosed herein are methods for separating ionic impurities from monosaccharide processing streams using simulated moving bed chromatography. 1. A method of separating an ionic impurity from a monosaccharide-containing process stream , comprising:a. contacting an ion exclusion resin within a simulated moving bed chromatography unit with the monosaccharide-containing process stream; andb. eluting the ion exclusion resin with water to produce an extract stream that comprises monosaccharides and a raffinate stream that comprises the ionic impurity,thereby separating the ionic impurity from the monosaccharide-containing process stream.2. A method of separating an ionic impurity from a saccharide-containing process stream , comprising:a. providing the saccharide containing process stream, wherein the process stream further comprises an inorganic dianion;b. contacting an ion exclusion resin within a simulated moving bed chromatography unit with the saccharide-containing process stream; andc. eluting the ion exclusion resin with an aqueous eluent to produce an extract stream that comprises saccharides and a raffinate stream comprises the ionic impurity,thereby separating the ionic impurity from the saccharide-containing process stream.3. The method of claim 1 , wherein the method is continuous.4. The method of claim 1 , further comprising isolating the extract steam that comprises the monosaccharides or saccharides.5. The method of claim 1 , further comprising isolating the raffinate stream that comprises water soluble inorganic and organic salts of sodium and ammonium.6. The method of claim 5 , wherein the water soluble inorganic salts of sodium and ammonium comprise sodium sulfate and ammonium sulfate.7. The method of claim 5 , wherein the water soluble organic salts of sodium and ammonium comprise sodium aldonate and ammonium aldonates.8. The method of claim 1 , wherein the monosaccharide or saccharide containing process stream comprises an L-monosaccharide.9. The ...

Подробнее
23-01-2014 дата публикации

NOVEL FUCOSYLTRANSFERASES AND THEIR APPLICATIONS

Номер: US20140024820A1
Принадлежит: JENNEWEIN BIOTECHNOLOGIE GMBH

The present invention relates to nucleic acid and amino acid sequences from serogroup O126, coding for/representing a novel alpha-1,2-fucosyltransferase. The invention also provides uses and methods for using the alpha-1,2-fucosyltransferase to generate fucosylated products, such as oligosaccharides, (glyco)proteins, or (glyco)lipids, in particular oligosaccharides found in human milk, such as 2′-fucosyllactose. 1. An isolated host cell for the production of a fucosylated oligosaccharide , the host cell comprising a nucleic acid sequence consisting of a polynucleotide encoding a polypeptide with alpha-1 ,2-fucosyltransferase activity and comprising a sequence selected from the group consisting of , a) the nucleic acid sequence shown in SEQ ID NO: 1 , b) a nucleic acid sequence complementary to SEQ ID NO: 1 , or c) nucleic acid sequences which hybridize under stringent conditions to the nucleic acid sequences defined in a) and b) or their complementary strands , wherein the nucleic acid sequence is a sequence foreign to the host cell and wherein the nucleic acid sequence is integrated in the genome of the host cell , or containing a vector comprising said nucleic acid sequence , wherein the nucleic acid sequence being operably linked to control sequences recognized by a host cell transformed with the vector.2. The isolated host cell according to claim 1 , wherein the host cell is selected from the group consisting of fungi including yeast claim 1 , bacteria claim 1 , insect claim 1 , animal and plant cells.3Escherichia coli. The isolated host cell according to claim 1 , wherein the host cell is an cell.4. The isolated host cell according to claim 1 , wherein the nucleic acid sequence consisting of the polypeptide encoding the polypeptide with alpha-1 claim 1 ,2-fucosyltransferase activity is adapted to the codon usage of the respective cell.5. A method for producing fucosylated oligosaccharides comprising the steps of:a) providing a polypeptide with alpha-1,2- ...

Подробнее
06-02-2014 дата публикации

PHOSPHONATE NUCLEOSIDES USEFUL AS ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS, AND INTERMEDIATES FOR THEIR PRODUCTION

Номер: US20140039179A1
Принадлежит:

The invention is directed to processes of preparing phosphonate nucleosides comprising a phosphonalkoxy-substituted five-membered, saturated or unsaturated, oxygen-containing ring coupled to a heterocyclic nucleobase such as a pyrimidine or purine base. These compounds can be described by general formula (II) 2. The process of claim 1 , wherein Ris an O-benzoyl group.3. The process of claim 1 , wherein the Lewis acid catalyst is SnCl.4. The process of claim 1 , further comprising a step of N-protecting the nucleobase with an acyl group prior to the coupling step.5. The process of claim 4 , wherein the acyl group is a benzoyl group or an acetyl group.6. The process of claim 1 , wherein the coupling step is carried out from 0° C. to room temperature.7. The process of claim 1 , further comprising a step of silylating the nucleobase prior to the coupling step.8. The process of claim 7 , wherein silylating is performed with hexamethyldisilane.9. The process of claim 8 , wherein silylating is performed in the presence of ammonium sulphate.10. The process of claim 1 , wherein Ris ORand Ris hydrogen claim 1 , further comprising a step of selectively protecting Rprior to the coupling step.11. The process of claim 1 , wherein Rand Rare each isopropyl.12. The process of claim 1 , wherein Ris benzyl.13. The process of claim 1 , wherein n is 1.14. The process of claim 11 , wherein Ris benzyl.15. The process of claim 11 , wherein n is 1.16. The process of claim 12 , wherein n is 1.17. The process of claim 4 , further comprising a step of deprotecting the nucleobase after the coupling step claim 4 , said deprotecting step being performed under basic conditions.18. The process of claim 17 , wherein said deprotecting step is performed with saturated ammonia in methanol.19. The process of claim 1 , wherein Rand Rare each hydrogen claim 1 , further comprising a final hydrolysis step.20. The process of claim 19 , wherein said final hydrolysis step is performed by treatment with a ...

Подробнее
13-02-2014 дата публикации

NOVEL GLYCOSYL PHOSPHITES

Номер: US20140046044A1
Принадлежит: GLYCOM A/S

The present invention relates to providing compounds of general formula 1 2. The compound according to claim 1 , wherein A is a protected sialyl or fucosyl moiety claim 1 , and R is optionally substituted aryl.5. A method for producing a compound of general formula 1 as defined in claim 1 , characterized in that a compound of formula A-OH claim 1 , wherein A means a protected glycosyl residue of a mono- claim 1 , di- or oligosaccharide is{'sub': '2', 'a) reacted with a compound (RO)PY wherein R is selected from optionally substituted aryl and optionally substituted heteroaryl, and Y is selected from halogen and dialkylamino, or'}{'sub': '3', 'b) reacted with a compound PXwherein X is halogen, followed by reaction with an alcohol ROH wherein R is defined as above.'}6. The method according to claim 5 , wherein the compound of A-OH is N-acetyl neuraminic acid tetraacetate methyl ester or 2-O-benzyl-3 claim 5 ,4-di-O-(optionally substituted acyl)-L-fucose claim 5 , PXis PCl claim 5 , and the alcohol ROH is phenol optionally substituted with alkyl claim 5 , alkoxy and/or halogen claim 5 , preferably methyl claim 5 , methoxy and/or bromo.7. A process for the synthesis of an oligosaccharide claim 1 , characterized in that the said synthesis comprises at least the step of: coupling a compound of general formula 1 as defined in with an acceptor of the formula B—OH claim 1 , wherein B—OH means a protected mono- claim 1 , di- or oligosaccharide.10. The process according to for the synthesis of a sialylated or fucosylated human milk oligosaccharide claim 1 , wherein a compound of general formula 3A or 3B as defined in is coupled with an acceptor of the formula C—OH claim 1 , wherein C—OH means a protected desialo- or defuco-human milk oligosaccharide claim 1 , followed by deprotection to give the sialylated or fucosylated human milk oligosaccharide.11. The process according to claim 10 , wherein the sialylated or fucosylated human milk oligosaccharide is selected from 6′- ...

Подробнее
27-02-2014 дата публикации

Catalytic hydrogenolysis of a composition of a mixture of oligosaccharide precursors and uses thereof

Номер: US20140057868A1
Принадлежит: Glycom AS

A method for the manufacture of a mixture of human milk oligosaccharides is disclosed. The method involves the catalytic hydrogenolysis of compounds of the general formula 1 and 2. The use of compounds of general formula 1 and 2 in the manufacture of human milk oligosaccharides is also disclosed.

Подробнее
06-03-2014 дата публикации

Halogenated Di and Trisaccharides, Pharmaceutical Formulations, Diagnostic Kits and Methods of Treatment

Номер: US20140065062A1
Автор: Bahram Memarzadeh
Принадлежит: Bahram Memarzadeh

The present invention relates to a novel family of alkylated halogenated di- and trisaccharides which exhibit pharmaceutical efficacy in the areas of permeation enhancers, anti-microbial effects, anti-fugal effects, facilitation of diagnostic procedures. The invention further includes methods of treatment and diagnostic kits.

Подробнее
04-01-2018 дата публикации

OLIGOSACCHARIDE COMPOSITIONS FOR USE IN NUTRITIONAL COMPOSITIONS, AND METHODS OF PRODUCING THEREOF

Номер: US20180000146A1
Автор: GEREMIA John M.
Принадлежит:

Described herein are methods of producing prebiotic compositions that are made up of oligosaccharide compositions, as well as methods of using such prebiotic compositions in nutritional compositions and methods of producing such oligosaccharide and nutritional compositions. 1. A method of producing a prebiotic composition , comprising: wherein the catalyst comprises acidic monomers and ionic monomers connected to form a polymeric backbone, or', 'wherein the catalyst comprises a solid support, acidic moieties attached to the solid support, and ionic moieties attached to the solid support; and, 'combining feed sugar with a catalyst to form a reaction mixture, wherein the catalyst comprises acidic moieties and ionic moieties,'}producing a prebiotic composition from at least a portion of the reaction mixture2. The method of claim 1 , wherein the catalyst comprises acidic monomers and ionic monomers connected to form a polymeric backbone.3. The method of claim 2 , wherein each acidic monomer independently comprises at least one Bronsted-Lowry acid.4. The method of or claim 2 , wherein each ionic monomer independently comprises at least one nitrogen-containing cationic group claim 2 , at least one phosphorous-containing cationic group claim 2 , or a combination thereof.5. The method of claim 1 , wherein the catalyst comprises a solid support claim 1 , acidic moieties attached to the solid support claim 1 , and ionic moieties attached to the solid support.6. The method of claim 5 , wherein the solid support comprises a material claim 5 , wherein the material is selected from the group consisting of carbon claim 5 , silica claim 5 , silica gel claim 5 , alumina claim 5 , magnesia claim 5 , titania claim 5 , zirconia claim 5 , clays claim 5 , magnesium silicate claim 5 , silicon carbide claim 5 , zeolites claim 5 , ceramics claim 5 , and any combinations thereof.7. The method of or claim 5 , wherein each acidic moiety independently has at least one Bronsted-Lowry acid.8. The ...

Подробнее
07-01-2016 дата публикации

PROCESS FOR REMOVING FORMALDEHYDE FROM A COMPOSITION COMPRISING GLYCOLALDEHYDE

Номер: US20160002137A1
Принадлежит: Haldor Topsoe A/S

A process for reducing the percentage by weight of formaldehyde present in a composition comprising glycolaldehyde, wherein formaldehyde is transformed into one or more formaldehyde acetal(s) and removed from the reactive distillation reaction solution by reactive distillation in the presence of at least one alcohol and a catalyst. 1. A process for reducing the percentage by weight of formaldehyde present in a composition comprising glycolaldehyde by reactive distillation in the presence of at least one alcohol and at least one catalyst.2. A process according to claim 1 , wherein the alcohol is selected from one or more of the group consisting of methanol claim 1 , ethanol claim 1 , ethylene glycol and propylene glycol.3. A process according to claim 1 , wherein the catalyst is an acid catalyst.4. A process according to claim 1 , wherein the catalyst is selected from one or more of the group consisting of a solid catalyst claim 1 , mineral acid catalyst and organic acid.5. A process according to claim 1 , wherein the acid catalyst is selected from one or more of the group consisting of an acidic resin claim 1 , molecular sieves and a mineral acid.6. A process according to claim 1 , wherein the acid catalyst is selected from one or more of the group consisting of Amberlyst-131 and concentrated sulphuric acid.7. A process according to claim 1 , wherein the composition comprising glycolaldehyde is an aqueous composition.8. A process according to claim 1 , wherein the volume ratio of alcohol to aqueous composition comprising glycolaldehyde is between 1:9 and 9:1.9. A process according to claim 1 , wherein the reactive distillation is carried out at a temperature less than 120° C.10. A process according to claim 1 , wherein the reactive distillation is carried out under reduced pressure.11. A process according to claim 1 , wherein the process further comprises adding a catalyst and optionally water to the reaction solution after reactive distillation claim 1 , heating ...

Подробнее
07-01-2021 дата публикации

OLIGOSACCHARIDE COMPOSITIONS AND METHODS FOR PRODUCING THEREOF

Номер: US20210002387A1
Принадлежит:

Described herein are methods for the production of oligosaccharides, including functionalized oligosaccharides, from one or more sugars, such as one or more monosaccharides, using polymeric and solid-supported catalysts containing acidic and ionic groups. Also provided are the oligosaccharide compositions, including functionalized oligosaccharide compositions, obtained using the methods. 126-. (canceled)27. An oligosaccharide composition prepared according to a method comprising condensation polymerization of one or more sugars to produce the oligosaccharide composition; wherein:', 'each of the monosaccharide monomers is selected from the group consisting of C5 monosaccharides and C6 monosaccharides; at least 15% of the oligosaccharide composition has a degree of polymerization (DP) of at least four; 5 to 25% of the oligosaccharide composition has a degree of polymerization (DP) of three; and 5 to 30% of the oligosaccharide composition has a degree of polymerization (DP) of two;', 'the mean DP of the oligosaccharide composition is 10-15; and, 'monosaccharide monomers connected by glycosidic bonds;'}, 'the oligosaccharide composition comprisingat least a portion of the glycosidic bonds in the oligosaccharide composition comprises β-1,2 bonds and α-1,3 bonds.28. The oligosaccharide composition of claim 27 , wherein the monosaccharide monomers are glucose claim 27 , galactose claim 27 , xylose claim 27 , arabinose claim 27 , fructose claim 27 , mannose claim 27 , ribose claim 27 , allose claim 27 , fucose claim 27 , or rhamnose.29. The oligosaccharide composition of claim 27 , wherein the monosaccharide monomers are connected by glycosidic bonds to form oligomer backbones claim 27 , and wherein the oligomer backbones are optionally substituted with one or more pendant functional groups claim 27 , wherein the pendant functional groups are carboxylic acids claim 27 , sugar alcohols claim 27 , amino acids claim 27 , amino sugars claim 27 , alcohols claim 27 , sulfate ...

Подробнее
07-01-2021 дата публикации

Method for Preparation of Derivatives of Gram-Positive Bacteria Surface Capsular Polysaccharide

Номер: US20210002388A1
Автор: CAI Juntao, Hu Jing, YIN Jian
Принадлежит:

The present disclosure discloses a method for preparation of derivatives of gram-positive bacteria surface capsular polysaccharide, and belongs to the field of carbohydrate chemistry. The present disclosure takes glucose as a glycosyl donor to obtain a target β-glucosidic bond, then successfully synthesizes a disaccharide building block through a method of redox of a glucose C-2 site, and then takes the disaccharide building block as a repeat unit to synthesize a target oligosaccharide structure such as a derivative [→3)-α-D-Manp-(1→4)-β-D-Rhap-(1→]-Linker of gram-positive bacteria cell wall capsular polysaccharide. A reduction end of decose is linked with a linker to be linked with a protein to make glycoconjugates for immunological studies. The method provided by the present disclosure is simple, time-saving, labor-saving and low-cost, and the resultant derivatives of the gram-positive bacteria surface capsular polysaccharide may be used for development and preparation of medicine related to autism. 3. The method according to claim 2 , wherein the synthesizing the gram-positive bacteria cell wall capsular polysaccharide compound comprises the following steps: taking carbohydrate building block 1 as a glycosyl donor claim 2 , taking carbohydrate building block 2 as a glycosyl receptor claim 2 , dissolving the glycosyl donor and the glycosyl receptor in dry methylene dichloride claim 2 , adding a molecular sieve claim 2 , then performing lewis acid catalysis claim 2 , and stirring at a certain temperature for reaction for 2 to 10 hours to prepare 1 claim 2 ,4-α-linked disaccharide fragment 3;or on the basis of step (1),4. The method according to claim 3 , further comprising taking carbohydrate building block 4 as a glycosyl donor claim 3 , taking carbohydrate building block 5 as a glycosyl receptor claim 3 , dissolving the glycosyl donor and the glycosyl receptor in dry methylene dichloride claim 3 , adding a molecular sieve claim 3 , then performing lewis acid ...

Подробнее
03-01-2019 дата публикации

System for hydrogen production under limited aerobic conditions

Номер: US20190002924A1
Принадлежит: Harbin Institute of Technology

The present invention provides a method for fermentative hydrogen production under limited aerobic conditions by utilizing the respiratory interaction between a strictly anaerobic hydrogen producing bacterium, YUAN-3, and a facultative anaerobic bacterium, PAO1. The two bacteria are co-cultured to produce hydrogen gas in a culture medium without any anaerobic treatment. Sucrose, lactose or glucose are used as the carbon source for the co-culture which can promote the growth of YUAN-3 and reduce substrate competition between two bacteria. L-cysteine is added to increase the hydrogen yield and the production rate. Using 15 g/L glucose and 5 mmol/L L-cysteine, the invented method achieved the hydrogen production yield of 1.11 mol-hydrogen/mol-glucose. 1. A method for hydrogen production under limited aerobic conditions , comprising:{'i': E. harbinense', 'P. aeruginosa, 'a, co-culturing YUAN-3 and PAO1 in a liquid medium containing 10 to 20 g/L sucrose or lactose in a sealed container at 35° C.; and'}b, collecting hydrogen gas at 1 to 50 hours after the start of the co-culture.2. (canceled)3. The method of claim 1 , wherein the liquid medium contains 15 g/L sucrose or lactose.4. The method of claim 1 , wherein the liquid medium further comprises 0 to 15 mmol/L of L-cysteine.5. The method of claim 1 , wherein the liquid medium further comprises 5 to 10 mmol/L of L-cysteine.6. The method of claim 1 , wherein the liquid medium comprises 5 mmol/L of L-cysteine.7. The method of claim 1 , wherein the liquid medium comprises 4 g peptone claim 1 , 1 g yeast extract claim 1 , 2 g beef extract claim 1 , 4 g NaCl claim 1 , 1.0 g KHPOand 0.2 g MgCl.6HO per liter.8E. harbinenseP. aeruginosa. The method of claim 1 , wherein 0.1-0.2 g of YUAN-3 and 0.08-0.12 g of PAO1 are inoculated into the liquid medium.9. The method of claim 1 , wherein during the sealed culture claim 1 , a shaker or a magnetic stirrer is used for agitation and culture; wherein conditions for culturing using the ...

Подробнее
10-01-2019 дата публикации

Mobile Solid Phase Reaction System and Method

Номер: US20190009241A1
Принадлежит:

A system and method are disclosed. A system for contacting a mobile solid phase with a flowing fluid phase includes: one or more reaction module, wherein the one or more reaction module comprises a conduit for the passage of a fluid phase and a solid phase, the conduit comprising a fluid input port and a fluid outlet port, and a first service module operably connected to a first side of a reaction module, the first service module for supplying and/or receiving the fluid phase to and/or from the reaction module, wherein the system is configured for passing a solid phase through the reaction module, via the conduit. 1. A system for contacting a mobile solid phase with a flowing fluid phase comprising: 'wherein the first reaction module comprises a conduit for the passage of a fluid phase and a solid phase, the conduit comprising a fluid input port and a fluid outlet port; and', 'a first reaction module;'}a first service module operably connected to a first side of the first reaction module, the first service module for supplying and/or receiving the fluid phase to and/or from the first reaction module;wherein the system is configured for passing a solid phase through the first reaction module, via the conduit.2. The system as claimed in further comprising a second reaction module claim 1 , provided in series claim 1 , such that the solid phase may pass through the consecutive reaction modules.3. The system as claimed in wherein the two reaction modules claim 2 , and the first service module claim 2 , are all configured to releasably connect to adjacent modules.4. The system as claimed in claim 1 , wherein the first side and a further side of the first reaction module are each a mating face; andwherein the first service module has a mating face that is connectable with a respective mating face of the first reaction module.5. The system as claimed in claim 1 , wherein the conduit of the first reaction module comprises a solid phase input port and a solid phase output ...

Подробнее
08-01-2015 дата публикации

Method for the manufacture of concentrated aqueous solutions of alkali metal salt of carboxymethyl fructan

Номер: US20150011748A1
Принадлежит: ITALMATCH CHEMICALS SPA

A method is for the manufacture of aqueous solutions of alkali metal salt of carboxymethyl fructan. More specifically the method for the manufacture of aqueous solutions includes at least 20% by weight of alkali metal salt of carboxymethyl fructan having a degree of carboxymethyl substitution of at least 1.2.

Подробнее
14-01-2021 дата публикации

Method for producing allulose crystals

Номер: US20210009619A1
Принадлежит: TATE AND LYLE INGREDIENTS AMERICAS LLC

Allulose crystals are efficiently produced from an allulose syrup using seed crystals.

Подробнее
21-01-2021 дата публикации

DETECTION OF OLIGOSACCHARIDES

Номер: US20210017570A1
Принадлежит: Biomarin Pharmaceutical Inc.

Provided herein are processes for detecting oligosaccharides in a biological sample. In specific instances, the biological sample is provided from an individual suffering from a disorder associated with abnormal glycosaminoglycan accumulation. 130-. (canceled)31. A method of determining in an individual the presence , identity , and/or severity of an MPS IIIA or MPS IIIB disorder , the method comprising:(a) generating a biomarker comprising one or more saturated non-reducing end oligosaccharides, wherein the biomarker is generated by treating a population of heparan sulfate oligosaccharides, in or isolated from a biological sample from the individual, with at least one digesting glycosaminoglycan lyase, wherein prior to lyase treatment, the biomarker is not present in abundance in samples from individuals with the MPS IIIA or MPS IIIB disorder relative to individuals without the MPS IIIA or MPS IIIB disorder; and(b) using an analytical instrument to detect the presence of and/or measure the amount of the biomarker produced and displaying or recording the presence of or the measure of the biomarker produced;wherein the presence of and/or measure of the amounts of the biomarker are utilized to determine the presence, identity, and/or severity of the MPS III disorder; andwherein the biomarker is selected from a group consisting of{'sub': '3', 'Formula III: [GlcNS-IdoA-GlcN(Ac)0-1](SOR)0-3;'}{'sub': '3', 'Formula IV: [GlcNS-GlcA-GlcN(Ac)0-1](SOR)0-2;'}{'sub': '3', 'Formula V: [GlcNAc-IdoA-GlcN(Ac)0-1](SOR)0-3;'}{'sub': '3', 'Formula VI: [GlcNAc-GlcA-GlcN(Ac)0-1](SOR)0-2;'}{'sub': '3', 'Formula VIII: [GlcN-GlcA-GlcN(Ac)0-1](SOR)0-4;'}{'sub': '3', 'Formula IX: [GlcNAc6S-IdoA-GlcN(Ac)0-1](SOR)0-3;'}{'sub': '3', 'Formula X: [GlcNAc6S-GlcA-GlcN(Ac)0-1](SOR)0-2;'}GlcN-IdoA-GlcNAc;GlcN-IdoA2S-GlcNAc;GlcN-IdoA-GlcNS;GlcN-IdoA-GlcNAc6S;GlcN-IdoA2-GlcNAc6S; andGlcN-IdoA-GlcNS6S.32. The method of claim 31 , wherein the biomarker is of Formula V: [GlcNAc-IdoA-GlcN(Ac)-1](SOR); or ...

Подробнее
22-01-2015 дата публикации

INOSITOL AND TREHALOSE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES COMPRISING THE SAME

Номер: US20150025035A1
Принадлежит: POSTECH ACADEMY-INDUSTRY FOUNDATION

The invented inositol and trehalose derivatives, prepared by introducing multiple units of the guanidine group to the backbone molecules, show excellent blood-brain barrier permeability, and accordingly, it can be easily transported to the brain tissues and utilized for the treatment of neurodegenerative diseases such as Alzheimer's disease and Huntington's disease. 2. A pharmaceutical composition containing the compound according to or a salt thereof as an active ingredient.3. A method for treating a neurodegenerative disease claim 2 , comprising administering the pharmaceutical composition of to a subject in need thereof.4. The method according to claim 3 , wherein the neurodegenerative disease is Alzheimer's disease claim 3 , Huntington's disease claim 3 , or other closely related diseases. This application is a divisional of U.S. patent application Ser. No. 13/003,414, filed Jan. 10, 2011, which is a national stage application of PCT/KR2009/001470 filed Mar. 23, 2009, which claims priority from Korean Patent Application No. 10-2008-0071383 filed Jul. 22, 2008, the disclosure of which is incorporated herein by reference in its entirety.The present invention relates to inositol and trehalose derivatives having excellent blood-brain barrier permeability, which are prepared by introducing several guanidine groups to the backbone of inositol and trehalose, and to pharmaceutical compositions for treating neurodegenerative diseases comprising the same.Approximately 25 million people worldwide are currently suffering from Alzheimer's disease, and that number is expected to double every five years. Studies of the brain tissue of Alzheimer's disease patients have revealed the presence of aggregated peptides, particurally senile plaques and neurofibrillary tangles, which have been reported to be formed from mutated beta-amyloids and Tau peptides (M. Goedert, M. G. Spillantini, 314: 777-784 (2006)). Such aggregated peptides induce cell damage and apoptosis, resulting in ...

Подробнее
22-01-2015 дата публикации

GANGLIOSIDE COMPOSITIONS

Номер: US20150025234A1
Принадлежит:

The invention provides novel gangliosides and mixtures of novel gangliosides, and drug products containing the same. The invention also provides cells induced to over-express one or more gangliosides. The invention further provides methods for production of gangliosides, e.g., GM1, from cells in culture using, for example, bone marrow cells and neuroblastoma cells. Methods include the treatment of cells with neural induction media and chloroquine, or chloroquine alone in the case of, e.g., human bone marrow cells, neuraminidase or glucosamine, to induce the production of gangliosides, e.g., GM1, in the cells. Also provided are methods of long-term, high density culturing of cells without passaging to produce gangliosides, e.g., GM1. Methods of quantifying gangliosides, e.g., GM1 in cell culture are also provided. 1. A ganglioside characterized by a single thin layer chromatography (“TLC”) band having a retardation factor (“Rf”) value that is greater than an ovine GM1 standard Rf when said ganglioside is subjected to TLC on a glass plate coated with a 250 μm layer of ultrapure silica gel and contacted with a solution comprising chloroform , methanol and 0.2% calcium in a ratio of 50:42:11 , after which said coated glass plate is stained by being placed into a second solution comprising 80 mL of concentrated hydrochloric acid , 0.25 mL of 0.1 M cupric sulfate , 10 mL of 2% resorcinol and 10 mL of water , and said glass plate is heated in said second solution for 20 minutes at 100° C. , wherein said ganglioside comprises one or more gangliosides.2. The ganglioside of claim 1 , wherein said ganglioside is purified from a crude ganglioside mixture.3. The ganglioside of claim 2 , wherein said crude ganglioside mixture is isolated from adult human bone marrow stromal cells cultured under low oxygen.4. The ganglioside of claim 3 , wherein said low oxygen is 5% oxygen.5. The ganglioside of claim 1 , wherein said ganglioside Rf value is 0.65.6. The ganglioside of claim 1 , ...

Подробнее
10-02-2022 дата публикации

METHOD FOR SEPARATING BIOMASS FROM A SOLUTION COMPRISING BIOMASS AND AT LEAST ONE OLIGOSACCARIDE

Номер: US20220041638A1
Принадлежит:

The present invention relates to a method for separating biomass from a solution comprising biomass and at least one oligosaccharide.comprising providing the solution comprising biomass and oligosaccharides.lowering the pH value of the solution below 7 by adding at least one acid to the solution comprising biomass and the at least one oligosaccharide. adding an adsorbing agent to the solution comprising biomass and oligosaccharides. and carrying out first membrane filtration so as to separate the biomass from the solution comprising the at least one oligosaccharide. 115.-. (canceled)16. A method for separating biomass from a solution comprising biomass and at least one oligosaccharide , comprising:providing the solution comprising biomass and oligosaccharides;setting the pH value of the solution below 7 by adding at least one acid to the solution comprising biomass and the at least one oligosaccharide;adding at least one adsorbing agent to the solution comprising biomass and oligosaccharides; andcarrying out a first membrane filtration, so as to separate the biomass from the solution comprising at least one oligosaccharide.17. The method according to claim 16 , wherein the pH value of the solution is lowered to a pH value in the range of 3.0 to 5.5.18. The method according to claim 16 , wherein said at least one acid is an acid selected from the group consisting of HSO claim 16 , HPO claim 16 , HCl claim 16 , HNOand CHCOH.19. The method according to claim 16 , wherein said adsorbing agent is added in an amount in the range of 0.5% to 3% by weight.20. The method according to claim 16 , wherein said adsorbing agent is added as a powder having a particle size distribution with a diameter d50 in the range of 2 μm to 25 μm.21. The method according to wherein said adsorbing agent is added as a suspension of the powder in water.22. The method according to claim 16 , wherein said first membrane filtration is carried out as cross-flow microfiltration or cross-flow ...

Подробнее
10-02-2022 дата публикации

IRON COMPLEX COMPOUNDS FOR THERAPUTIC USE

Номер: US20220041640A1
Принадлежит:

The present invention relates to iron complex compounds for therapeutic use which are low in arsenic, chromium, lead, cadmium, mercury and/or aluminum, compositions thereof and processes for preparing said iron complex compounds. 115-. (canceled)16. A process for preparing an iron carbohydrate complex compound comprising the steps of a. decomposing iron pentacarbonyl;', 'b. recrystallization of an iron salt from an aqueous solution thereof', 'c. extracting an aqueous iron salt solution with an organic solvent and recovering the iron salt by stripping the organic solvent;', 'd. precipitation at an anode during electrolysis of an aqueous iron salt solution;', 'e. contacting an aqueous iron salt solution with a base so as to form a precipitate of iron hydroxide and separating the precipitate from the liquid by filtration or centrifugation; or', 'f. distillation of ferric chloride from a mixture comprising ferric chloride and non-volatile impurities, wherein, '(i) obtaining an iron preparation by'}the iron preparation comprises iron in a form selected from a water-soluble iron salt, an iron hydroxide or an iron oxide-hydroxide,the amount of arsenic in the iron preparation does not exceed 4.5 μg per g of iron, andthe amount of lead in the iron preparation does not exceed 1.5 μg per g of iron; and(ii) reacting the iron preparation with a ligand in the presence of water so as to form the iron carbohydrate complex compound, and(iii) recovering said iron carbohydrate complex compound.17. The process of claim 16 , wherein recrystallization in step (i)(b) is recrystallization of ferric nitrate from an aqueous solution containing nitric acid.18. The process of claim 16 , wherein the aqueous iron salt solution of step (i)(c) is obtained during the processing of an iron-containing nickel ore.19. The process of claim 16 , wherein the organic solvent is an alcohol having about 4-20 carbon atoms or an organic solutions of an amine salt.20. The process of claim 16 , wherein the ...

Подробнее
10-02-2022 дата публикации

PRODUCTION OF BIOACTIVE OLIGOSACCHARIDES

Номер: US20220042057A1
Принадлежит:

Methods of generating oligosaccharides are provided. 120-. (canceled)21. A composition , comprising:a first 3Hex oligosaccharide;a first 4Hex oligosaccharide and a second 4Hex oligosaccharide; anda first 5Hex oligosaccharide and a second 5Hex oligosaccharide;wherein the first 4Hex oligosaccharide and the second 4Hex oligosaccharide are different isomers; andwherein the first 5Hex oligosaccharide and the second 5Hex oligosaccharide are different isomers.22. The composition of claim 21 , further comprising:a second 3Hex oligosaccharide and a third 3Hex oligosaccharide;wherein the first 3Hex oligosaccharide, the second 3Hex oligosaccharide, and the third 3Hex oligosaccharide are different isomers.23. The composition of claim 21 , further comprising:a third 4Hex oligosaccharide and a fourth 4Hex oligosaccharide;wherein the first 4Hex oligosaccharide, the second 4Hex oligosaccharide, the third 4Hex oligosaccharide, and the fourth 4Hex oligosaccharide are different isomers.24. The composition of claim 21 , further comprising:a third 5Hex oligosaccharide;wherein the first 5Hex oligosaccharide, the second 5Hex oligosaccharide, and the third 5Hex oligosaccharide are different isomers.25. The composition of claim 24 , further comprising:a fourth 5Hex oligosaccharide and a fifth 5Hex oligosaccharide;wherein the first 5Hex oligosaccharide, the second 5Hex oligosaccharide, the third 5Hex oligosaccharide, the fourth 5Hex oligosaccharide, and the fifth 5Hex oligosaccharide are different isomers.26. The composition of claim 25 , further comprising:a third 3Hex oligosaccharide; anda third 4Hex oligosaccharide;wherein:the first 3Hex oligosaccharide, the second 3Hex oligosaccharide, and the third 3Hex oligosaccharide are different isomers; andthe first 4Hex oligosaccharide, the second 4Hex oligosaccharide, and the third 4Hex oligosaccharide are different isomers.27. The composition of claim 21 , further comprising:a first 6Hex oligosaccharide.28. The composition of claim 27 , further ...

Подробнее
29-01-2015 дата публикации

SUGAR COMPOSITIONS

Номер: US20150028255A1
Автор: Eyal Aharon, Jansen Robert
Принадлежит:

A sugar composition comprising at least 40% dissolved solids in an aqueous solution having a viscosity at least 10% lower than a 42 DE (Dextrose Equivalents) reference solution with a same dissolved solids concentration at a given temperature. Another sugar composition comprising at least 30% glucose relative to total sugars, at least 10% mannose relative to total sugars, at least 5% xylose relative to total sugars, and less than 0.25% ash. Another sugar composition comprising at least 30% glucose relative to total sugars at least 10% mannose relative to total sugars, at least 5% xylose relative to total sugars, and at least 2% total furfurals. 159-. (canceled)60. A composition comprising: (i) a monomeric hemicellulose sugar hydrolyzate; or', '(ii) a monomeric cellulose sugar hydrolyzate;, '(a) at least one water-soluble monomeric hydrolyzate selected from (iii) a dimeric or higher oligomeric hemicellulose sugar hydrolyzate; or', '(iv) a dimeric or higher oligomeric cellulose sugar hydrolyzate; and, '(b) at least one water-soluble dimeric or higher oligomeric hydrolyzate selected from(c) less than 0.25% in total by weight, relative to the total solids in the composition, of ash.61. The composition of claim 60 , wherein the ash comprises Ca claim 60 , Cu claim 60 , Fe claim 60 , K claim 60 , Mg claim 60 , Mn claim 60 , Na claim 60 , P claim 60 , S claim 60 , and Si.62. The composition of claim 60 , wherein:the water-soluble monomeric hydrolyzate is selected from glucose, mannose, or a combination thereof; andthe water-soluble dimeric or higher oligomeric hydrolyzate is selected from a dimer or higher oligomer of glucose, mannose, or a combination thereof.63. The composition of claim 60 , wherein:the water-soluble monomeric hydrolyzate is selected from glucose, mannose, galactose, or a combination thereof; andthe water-soluble dimeric or higher oligomeric hydrolyzate is selected from cellobiose, isomaltose, trehalose, or a combination thereof.64. The composition of ...

Подробнее
01-02-2018 дата публикации

PROCESS FOR PREPARING HIGH-PURITY L-ARABINOSE BY USING ARABIC GUM AS RAW MATERIAL

Номер: US20180030077A1
Принадлежит: Zhejiang University

The present invention discloses a process for preparing L-arabinose from Gum Arabic comprising the steps of catalytical hydrolysis of L-arabinose from gum arabic followed by the purification steps including neutralization using alkali, adsorption bleaching, electrodialysis desalination, adsorption separation of impurities and crystallization, with the absolute purity of L-arabinose up to 98% and the recovery as high as 25%˜29% of material weight. The disclosed process has such advantages as low cost, environmental-friendliness and simple operation, showing promising in industrial production. 1. A process for preparing high-purity L-arabinose from gum arabic , the process comprising the follows steps:(1) adding dissolved gum arabic into an inorganic acid to form a mixed solution, controlling pH value of the solution at 0.2˜1, undertaking hydrolysis reaction at the temperature at 70˜100° C., after the reaction, neutralizing the hydrolysate by adding an alkali aqueous solution to pH about 4—7 and obtaining the neutralized hydrolysate containing L-arabinose;(2) adding the hydrolysate of step (1) to a fixed bed equipped with adsorbent A continuously, collecting the effluent to form a decolored solution;(3) passing the decolored solution of step (2) through a microporous membrane of the drainage to obtain a pretreatment solution, then desalinating the pretreatment solution with selectroosmosis to obtain a desalination solution;(4) passing the desalination solution of step (3) through a fixed bed equipped with adsorbent B continuously under room temperature, collecting an effluent, obtaining a supersaturated syrup by concentrating the effluent under reduced pressure at 45˜60° C.;(5) crystallizing the supersaturated syrup and obtaining white powder of L-arabinose after drying.2. The process for preparing high-purity L-arabinose from gum arabic according to claim 1 , characterized in that the inorganic acid is sulfuric acid claim 1 , hydrochloric acid claim 1 , phosphoric ...

Подробнее
08-02-2018 дата публикации

FIBER-RICH MALTOOLIGOSACCHARIDES HAVING LOW GLUCOSE BIOAVAILABILITY, METHOD OF MANUFACTURE THEREOF AND USE THEREOF IN HUMAN FOOD AND ANIMAL FEED

Номер: US20180037599A1
Принадлежит: ROQUETTE FRERES

The present invention relates to maltooligosaccharides, the content of α-1,4-glycosidic bonds of which is between 70% and 80% of the total number of 1,4-type glycosidic bonds. The invention also relates to the method for manufacturing these maltooligosaccharides. Said maltooligosaccharides afford all the benefits of fiber-based foods, with an extremely low nutritional value. Such a compromise is particularly advantageous for use in healthy balanced diets, but also in the treatment and/or prevention of the pathology of diabetes. The invention also relates to the use of said maltooligosaccharides in the fields of human food and animal feed. 1. A method for manufacturing maltooligosaccharides comprising the steps consisting in:a) providing an aqueous solution of at least two carbohydrates, characterized in that 40% to 95% of the dry weight of said solution consists of maltose,b) placing the aqueous solution resulting from step a) in contact with at least one polyol and at least one inorganic or organic acid,c) optionally increasing the solids content of the aqueous solution resulting from step b) up to at least 75% by weight of the total weight thereof,d) carrying out a heat treatment on the aqueous solution resulting from step b) or optionally from step c), at a temperature of between 140° C. and 300° C. under a negative pressure of between 50 and 500 mbar.2. The method as claimed in claim 1 , characterized in that the aqueous solution resulting from step a) contains glucose.3. The method as claimed in claim 1 , characterized in that the aqueous solution resulting from step a) has a solids content of at least 50% claim 1 , preferably of at least 70% claim 1 , very preferably of at least 80% by weight of the total weight thereof claim 1 , and in any case of at most 95% by weight of the total weight thereof.4. The method as claimed in claim 1 , characterized in that the polyol is selected from glycerol claim 1 , erythritol claim 1 , xylitol claim 1 , arabitol claim 1 , ...

Подробнее
08-02-2018 дата публикации

GLUCOSE/GALACTOSE BIOSENSORS AND METHODS OF USING SAME

Номер: US20180037928A1
Принадлежит:

Provided herein are glucose and galactose biosensors and methods of making and using the same. 1. A biosensor comprising:{'i': 'E. coli', 'a) a polypeptide comprising a ligand binding site and (i) one or more mutations as compared to SEQ ID NO:112 (wild-type GGBP) that alter the ligand binding affinity of the polypeptide; and'}b) a reporter conjugated to the polypeptide,wherein when the polypeptide consists of a single mutation, the single mutation is F16C,wherein the ligand-bound biosensor results in a reporter-generated signal that is different from the unbound biosensor, andwherein the ligand is selected from the group consisting of glucose, galactose, and a combination thereof.2. The biosensor of claim 1 , wherein the reporter is conjugated to F16C.3. The biosensor of claim 1 , wherein the polypeptide further comprises (ii) at least one additional mutation that replaces an amino acid with a cysteine.4. The biosensor of claim 3 , wherein the reporter is conjugated to the cysteine.5. The biosensor of claim 1 , wherein(a) the biosensor comprises a single reporter;(b) the reporter comprises a fluorophore and wherein the signal is a fluorescent signal;(c) the reporter comprises a fluorophore and wherein the signal is a fluorescent signal, wherein the fluorophore is selected from the group consisting of acrylodan and badan;(d) the reporter comprises a fluorophore and wherein the signal is a fluorescent signal, wherein the signal comprises an emission intensity of the fluorophore recorded at one or more wavelengths;(e) the reporter comprises a fluorophore and wherein the signal is a fluorescent signal, wherein the change in signal comprises a shift in the one or more wavelengths;(f) the reporter comprises a fluorophore and wherein the signal is a fluorescent signal, wherein the signal comprises a ratio of emission intensities recorded at two or more wavelengths;(g) the reporter comprises a fluorophore and wherein the signal is a fluorescent signal, wherein the change ...

Подробнее
12-02-2015 дата публикации

COMPOSITIONS AND METHODS FOR DIRECT CAPTURE OF ORGANIC MATERIALS FROM PROCESS STREAMS

Номер: US20150041400A1
Принадлежит:

A particulate magnetic nanostructured solid sorbent (MNSS) material is described herein. The particles of the MNSS comprise a plurality of tethered nanoparticles. The nanoparticles are tethered together by substantially linear hydrocarbon chains, a poly(alkylene oxide) chains, or a combination thereof connecting the nanoparticles in a three-dimensional elastic network with the nanoparticles as junctions of the network having junction functionality of about 2.1 to about 6. The surfaces of at least some of the nanoparticles comprise a polymerized siloxane bearing at least one sorption-aiding substituent selected from a hydrophilic group and a lipophilic group. The plurality of nanoparticles is made up of superparamagnetic nanoparticles or a combination of superparamagnetic and non-magnetic nanoparticles. The individual superparamagnetic nanoparticles comprise a passivating metal oxide coating around a core comprising at least one nanocrystalline metal or alloy having ferromagnetic or ferrimagnetic properties. 1. A particulate magnetic nanostructured solid sorbent (MNSS) material , each particle of the MNSS comprising a plurality of nanoparticles tethered together by molecular chains comprising a substantially linear hydrocarbon , a poly(alkylene oxide) , or a combination thereof , the ends of the chains connecting the nanoparticles in a three-dimensional elastic network having junction functionality of about 2.1 to about 6 , with the nanoparticles as junctions of the network; the surfaces of at least some of the nanoparticles comprising a polysiloxane bearing sorption-aiding substituents selected from a hydrophilic substituents , lipophilic substituents , and a combination thereof; wherein the plurality of nanoparticles comprises superparamagnetic nanoparticles or a combination of superparamagnetic and non-magnetic nanoparticles; the superparamagnetic nanoparticles comprise a passivating metal oxide coating around a nanocrystalline metallic core; and the cores of the ...

Подробнее
06-02-2020 дата публикации

METHOD FOR PRODUCING ALLULOSE CRYSTALS

Номер: US20200040023A1
Принадлежит: Tate & Lyle Ingredients Americas LLC

Allulose crystals are efficiently produced from an allulose syrup using seed crystals. 1. A method for producing allulose crystals , wherein the method comprises:a) cooling and agitating a first admixture comprised of a first portion of allulose syrup and allulose seed crystals and initiating crystallization of allulose dissolved in the allulose syrup, thereby forming a first massecuite comprising allulose crystals and a first mother liquor containing residual dissolved allulose, the cooling and agitating being continued until a first preselected target yield of allulose crystals is achieved;b) optionally, separating the first massecuite into a first portion and a second portion;c) optionally, combining a second portion of allulose syrup with the second portion of the first massecuite to form a second admixture; andd) optionally, cooling and agitating the second admixture and initiating crystallization of allulose dissolved in the second portion of allulose syrup, thereby forming a second massecuite comprising allulose crystals and a second mother liquor containing residual dissolved allulose, the cooling and agitating being continued until a second preselected target yield of allulose crystals is achieved.2. The method of claim 1 , wherein at least steps a) and b) are performed.3. The method of claim 1 , wherein at least steps a) claim 1 , b) and c) are performed.4. The method of claim 1 , wherein at least steps a) claim 1 , b) claim 1 , c) and d) are performed.5. The method of claim 1 , wherein the first admixture is obtained by combining the first portion of allulose syrup and dry allulose crystals.6. The method of claim 1 , wherein the first admixture is obtained by combining with the first portion of allulose syrup and a heel comprised of allulose crystals and a mother liquor.7. The method of claim 1 , wherein the first admixture and second admixture are agitated in steps a) and d) claim 1 , if step d) is performed claim 1 , respectively using an agitator ...

Подробнее
15-02-2018 дата публикации

Pharmaceutical Composition of Killed Cells with Substantially Retained Immunogenicity

Номер: US20180042850A1
Принадлежит: CADILA PHARMACEUTICALS LTD.

The present invention relates to a lyophilized composition comprising killed cancer cells with substantially retained immunogenicity and morphology, an intracellular cryopreservative such as trehalose and an extracellular cryopreservative such as polyvinylpyrrolidone. The present invention also relates to a process for the preparation of said lyophilized composition. The lyophilized composition of the present invention can be used for cancer immunotherapy. 1. A lyophilized composition comprising:killed cancer cells with substantially retained immunogenicity and morphology;trehalose as an intracellular cryo-preservative at 1 to 10% w/v; andpolyvinyl pyrrolidone as an extra cellular cryo-preservative at 0.1 to 5% w/v.2. The lyophilized composition as claimed in claim 1 , wherein of polyvinyl pyrrolidone has molecular weight ranging from 30 to 50 kilo Daltons.3. The lyophilized composition as claimed in further comprising an adjuvant.4. The lyophilized composition as claimed in claim 3 , wherein adjuvant is selected from the group consisting of oils claim 3 , aluminium salts claim 3 , virosomes claim 3 , dead whole organisms claim 3 , extracts of microbes and combination thereof.5Mycobacterium. The lyophilized composition as claimed in claim 3 , wherein adjuvant is w (Mw).6. A process of preparing the lyophilized composition as claimed in claim 1 , comprising:f. Killing of cancer cells by any suitable method,g. treating killed cancer cells obtained from step-a with trehalose,h. treating killed cancer cells obtained from step-b with polyvinyl pyrrolidone,i. snap freezing killed cancer cells obtained from step-c, andj. lyophilizing killed cancer cells obtained from step-d.{'claim-ref': {'@idref': 'CLM-00006', 'claim 6'}, 'The process of preparing the lyophilized composition as claimed in , wherein the snap freezing is done at below −100° C.'} This application is a continuation in part application of a copending U.S. application Ser. No. 13/579,607, filed on Aug. 17, 2012 ...

Подробнее
06-02-2020 дата публикации

METHODS, DEVICES, AND KITS TO IMPROVE REDUCTION OR LABELING OF CARBOHYDRATES

Номер: US20200041522A1
Принадлежит: AGILENT TECHNOLOGIES, INC.

The present invention provides methods, devices, and kits to improve procedures for reducing carbohydrates, such as glycans released from glycoconjugates, or for labeling carbohydrates by reductive amination. 2. The method of claim 1 , further comprising step e′ claim 1 , washing any excess reductant or label from said first porous solid support using organic solvent or a solution with a concentration of organic solvent higher than 95% organic solvent following said reduction or labeling.3. The method of claim 2 , further comprising step e″ claim 2 , eluting said washed reduced or labeled carbohydrates from said first porous solid support using an aqueous solution comprising up to 20% organic solvent following said wash.4. The method of claim 3 , wherein said aqueous solution comprising up to 20% organic solvent comprises water or a buffer solution.5. The method of claim 3 , wherein said aqueous solution does not comprise any organic solvent.6. The method of claim 1 , wherein said first porous solid support is made of a hydrophilic material or has a hydrophilic material claim 1 , other than one bearing carboxyl groups claim 1 , on its surface.7. The method of claim 1 , wherein said first porous solid support is made of a hydrophilic material.8. The method of claim 6 , wherein said hydrophilic material is (a) cellulose claim 6 , (b) glass claim 6 , (c) alumina claim 6 , (d) silica claim 6 , (e) a functionalized surface containing diol claim 6 , aminopropyl claim 6 , carbamoyl claim 6 , cyanopropyl claim 6 , ethylenediamine-N-propyl claim 6 , (f) silica derivatized with diol claim 6 , aminopropyl claim 6 , or carbamoyl claim 6 , (g) a porous hydrophilic material other than one bearing one or more carboxyl groups claim 6 , or (h) a combination of two or more of these.9. The method of claim 8 , wherein said glass is glass fiber.10. The method of claim 1 , wherein said first porous solid support is made of a non-hydrophilic material or has a surface of non-hydrophilic ...

Подробнее
16-02-2017 дата публикации

PREPARATION METHOD FOR HIGH-PURITY 4'-GALACTOSYL-LACTOSE COMPOSITION

Номер: US20170044200A1
Принадлежит: KABUSHIKI KAISHA YAKULT HONSHA

A composition which has high 4′-GL purity and can be used as a reference standard for various analyses can be obtained by a more convenient method than one conventionally used. A method for preparing a high-purity 4′-GL composition includes the steps of: (A) subjecting a 4′-GL-containing galacto-oligosaccharide to activated carbon column chromatography, and performing stepwise elution with plural organic solvent aqueous solutions, wherein the organic solvent aqueous solutions are used such that the concentration of the organic solvent in the organic solvent aqueous solution is higher than the concentration of the organic solvent in the immediately preceding organic solvent aqueous solution with respect to a series of elutions; and (B) adding an organic solvent to the final fraction eluted in step (A), and crystallizing the 4′-GL. 1. A method for preparing a high-purity 4′-galactosyl-lactose (4′-GL) composition , the method comprising:(A) subjecting a 4′-GL-containing galacto-oligosaccharide to activated carbon column chromatography, and performing stepwise elution with plural organic solvent aqueous solutions, wherein the organic solvent aqueous solutions are used such that a concentration of an organic solvent in one organic solvent aqueous solution is higher than a concentration of the organic solvent in an immediately preceding organic solvent aqueous solution; and(B) adding an organic solvent to a final fraction eluted in said subjecting (A) and crystallizing the 4′-GL.2. The method according to claim 1 , wherein the concentration of the organic solvent in the organic solvent aqueous solutions used in said subjecting (A) is 10 to 30 mass %.3. The method according to claim 1 , wherein the stepwise elution in said subjecting (A) is performed with an organic solvent aqueous solution containing the organic solvent in a concentration of 10 to 20 mass % claim 1 , and subsequently an organic solvent aqueous solution containing the organic solvent in a concentration of ...

Подробнее
19-02-2015 дата публикации

SUGAR COMPOSITIONS

Номер: US20150048274A1
Автор: Eyal Aharon, Jansen Robert
Принадлежит:

A sugar composition comprising at least 40% dissolved solids in an aqueous solution having a viscosity at least 10% lower than a 42 DE (Dextrose Equivalents) reference solution with a same dissolved solids concentration at a given temperature. Another sugar composition comprising at least 30% glucose relative to total sugars, at least 10% mannose relative to total sugars, at least 5% xylose relative to total sugars, and less than 0.25% ash. Another sugar composition comprising at least 30% glucose relative to total sugars at least 10% mannose relative to total sugars, at least 5% xylose relative to total sugars, and at least 2% total furfurals. 165-. (canceled)66. A composition comprising:(a) at least one water-soluble monomeric hydrolyzate comprising a monomeric hemicellulose sugar hydrolyzate;(b) at least one water-soluble dimeric or higher oligomeric hydrolyzate comprising a dimeric or higher oligomeric hemicellulose sugar hydrolyzate; and(c) less than 0.25% in total by weight, relative to the total solids in the composition, of ash.67. The composition of claim 66 , wherein one or more of the water-soluble monomeric hydrolyzates is a pentose and one or more of the water-soluble dimeric or higher oligomeric hydrolyzate is a pentose.68. The composition of claim 66 , wherein the ash comprises Ca claim 66 , Cu claim 66 , Fe claim 66 , K claim 66 , Mg claim 66 , Mn claim 66 , Na claim 66 , P claim 66 , S claim 66 , and Si.69. The composition of claim 66 , wherein:the water-soluble monomeric hydrolyzate is selected from xylose, arabinose, or a combination thereof; andthe water-soluble dimeric or higher oligomeric hydrolyzate is selected from a dimer or higher oligomer of xylose, arabinose, or a combination thereof.70. The composition of claim 66 , wherein the water-soluble monomeric hydrolyzate is derived from a lignocellulose substrate.71. The composition of claim 66 , further comprising water.72. The composition of claim 66 , wherein the water-soluble monomeric ...

Подробнее
19-02-2015 дата публикации

GLYCOCONJUGATES AND USE THEREOF AS VACCINE AGAINST SHIGELLA FLEXNERI SEROTYPE 3a AND X

Номер: US20150050282A1
Принадлежит:

The present invention relates to compounds derived from sugars which reproduce the epitopes of serotypes 3a and X and to the use thereof for the preparation of vaccine compositions. More specifically, the subject matter of the present invention relates to novel glycoconjugated compounds comprising oligosaccharides or polysaccharides described hereinafter, to the method for synthesizing these oligosaccharides or polysaccharides and glycoconjugates, to derivatives of these oligosaccharides or polysaccharides, to compositions containing same, and also to the use of the glycoconjugates for vaccination purposes. Finally, the present invention relates to methods for diagnosing a infection using one or more oligosaccharides or polysaccharides or conjugates thereof. 111-. (canceled)14Shigella flexneri. A kit for diagnosis of an infection with of serotype 3a or X claim 12 , wherein it comprises at least one saccharide as claimed in .15. A method of preparation of the disaccharide (E)A (I) claim 12 , an intermediate in the synthesis of a saccharide as defined in claim 12 , wherein it comprises the following stages:condensation of the acceptor monosaccharide 31 with the donor monosaccharide 33 leading to the disaccharide 35;deacetylation of the disaccharide 35 to give the disaccharide 21; anddeprotection of the disaccharide 21 by hydrogenolysis of the benzyl groups to give the disaccharide (E)A.16. A method of preparation of the trisaccharide D(E)A (II) claim 12 , as defined in claim 12 , wherein it comprises the following stages:condensation of the donor monosacccharide 1 with the acceptor disaccharide 21 leading to the trisaccharide 22;deacetylation of the trisaccharide 22 leading to the trisaccharide 37; anddeprotection of the trisaccharide 37 to give the trisaccharide D(E)A.17. A method of preparation of the trisaccharide D(E)A (II) claim 12 , as defined in claim 12 , comprising the following stages:condensation of the donor monosacccharide 2 with the acceptor disaccharide ...

Подробнее
19-02-2015 дата публикации

CONVERSION OF CELLULOSE INTO SIMPLE SUGARS

Номер: US20150051391A1
Принадлежит: BAKER HUGHES INCORPORATED

Cellulose may be converted into simple sugars such as glucose by contacting the cellulose with a compound effective to catalytically cleave the ether bonds of the cellulose. The compound may be a vitamin, a porphyrin, flavins, pyridoxal-containing molecules, and/or a compound containing at least one ylide functional group. The cellulose may be carboxymethyl cellulose (CMC), which may be made by reacting cellulose with chloroacetic acid and a base such as NaOH. The compound may be vitamins (B1, B2, B6, or B12), phosphonium ylides, sulfonium ylides, sulfoxonium ylides, carbonyl ylides, oxonium ylides, asomethine ylides, iminium ylides, halonium ylides, and combinations thereof. The free glucose may be used for fermentation, converted to a biofuel and for other applications. 1. A method of converting cellulose into simple sugars comprising:in the presence of water, contacting cellulose with a compound effective to catalytically cleave ether bonds of the cellulose to give at least one simple sugar, where the compound is selected from the group consisting of vitamins, compounds with at least one ylide functionality, porphyrins, flavins, pyridoxal-containing molecules, and combinations thereof.2. The method of where the cellulose is carboxymethyl cellulose (CMC) made by a method comprising reacting crystalline cellulose with chloroacetic acid and a base selected from the group consisting of sodium hydroxide claim 1 , potassium hydroxide claim 1 , ammonium hydroxide and mixtures thereof.3. The method of where the compound is a compound containing at least one ylide functional group claim 1 , which is selected from the group consisting of vitamins claim 1 , phosphonium ylides claim 1 , sulfonium ylides claim 1 , sulfoxonium ylides claim 1 , carbonyl ylides claim 1 , oxonium ylides claim 1 , asomethine ylides claim 1 , iminium ylides claim 1 , halonium ylides claim 1 , flavins claim 1 , pyridoxal-containing molecules claim 1 , and combinations thereof.4. The method of where ...

Подробнее
03-03-2022 дата публикации

STABILIZED ACYCLIC SACCHARIDE COMPOSITE AND METHOD FOR STABILIZING ACYCLIC SACCHARIDES AND APPLICATIONS THEREOF

Номер: US20220064201A1
Принадлежит:

Disclosed is a stabilized acyclic saccharide composite, which includes a LDH-based (layered double hydroxide-based) material and acyclic saccharides intercalated in interlayer regions of the LDH-based material. The acyclic saccharides stabilized and trapped in the LDH-based material give an opportunity for direct functionalization to other valuable molecules in the pharmaceutical, chemical or carbohydrate industries. Further, a novel pathway for saccharide transformation and aldol condensation without the drawbacks associated with enzymatic catalysts is achieved through the acyclic saccharides trapped by the LDH-based material.

Подробнее
03-03-2022 дата публикации

GLYONIC LIQUIDS AND USES THEREOF

Номер: US20220064202A1

The present invention provides ionic liquids (ILs) comprising a carbohydrate anionic moiety and a cationic counter-ion moiety (Q) and methods for producing and using the same. In one particular embodiment, the carbohydrate anionic moiety portion of ILs of the present invention is of the formula: (I) wherein G is selected from the group consisting of a monosaccharide, a disaccharide, a trisaccharide, and a derivative thereof; and L is a moiety selected from the group consisting of: (IIA) (IIB) wherein each of R, R, and Ris independently hydrogen, Calkyl, or Cmono- or di-unsaturated alkenyl; Ais —CO, —POH, or —SO; and each of * marked carbon atom is independently a chiral center when said carbon atom has four different groups attached thereto.

Подробнее
13-02-2020 дата публикации

HYDRATED AND ANHYDROUS POLYMORPHS OF 2'-O-FUCOSYLLACTOSE AND THEIR PRODUCTION METHODS

Номер: US20200048294A1
Принадлежит:

This invention describes new hydrated and anhydrous polymorphs of 2′-0-ficosyllactose (2′FL): Polymorph A 2′FL-3/2HO, Polymorph B 2TL-5/2HO and anhydrous Polymorph C. There is also a description of the methods for obtaining them, and of a new method for preparing Polymorph I already known in the literature. 116.-. (canceled)17. 2′-O-Fucosyllactose (2′FL) in anhydrous crystalline form of polymorph C , wherein said polymorph C has characteristic XRPD peaks at 17.58±0.20 , 17.44±0.20 , 10.63±0.20 2Θ.18. A polymorph C according to claim 17 , having characteristic XRPD peaks at 17.58±0.20 claim 17 , 17.44±0.20 claim 17 , 10.63±0.20 claim 17 , 5.30±0.2 claim 17 , 20.05±0.20 2Θ.19. A polymorph C according to claim 17 , wherein the single crystal is arranged within a monocline system and the elementary cell has the following parameters: a=5.058(1) Å claim 17 , b=12.773(3) Å claim 17 , c=16.692(5) Å and a volume of 1074.75 Å.20. A method for preparing the polymorph C according to claim 17 , the method comprising crystallizing 2′FL from a C-Calcohol or mixtures thereof.21. A method for preparing the polymorph I claim 17 , having an X-ray powder diffraction with characteristic peaks at angles 2Θ 21.34±0.20° claim 17 , 20.92±0.20° claim 17 , 18.37±0.20° claim 17 , 16.70±0.20° claim 17 , 9.91±0.20° claim 17 , 13.13±0.20° claim 17 , 7.87±0.20° and 8.90±0.20° claim 17 , said method comprising the crystallization from glacial acetic acid.2223.-. (canceled)24. A method for obtaining crystalline 2′-O-Fucosyllactose (2′FL) anhydrate in form of polymorph C with molecular formula CHO claim 17 , the method comprising:{'sub': 1', '3', '18', '32', '15', '2, 'providing a mixture comprising (i) a C-Calcohol or mixture thereof and (ii) a 2′FL hydrate in form of polymorph A with molecular formula CHO.nHO wherein n is 3/2; and'}warming the mixture at a temperature in range of 30° C. to 70° C. for 1 hr to 24 hr, thereby crystallizing the 2′FL and forming 2′FL anhydrate in form of polymorph C ...

Подробнее
13-02-2020 дата публикации

HYDRATED AND ANHYDROUS POLYMORPHS OF 2'-O-FUCOSYLLACTOSE AND THEIR PRODUCTION METHODS

Номер: US20200048295A1
Принадлежит:

This invention describes new hydrated and anhydrous polymorphs of 2′-O-fucosyllactose (2′FL): Polymorph A 2′FL-3/2HO, Polymorph B 2TL-5/2 HO and anhydrous Polymorph C. There is also a description of the methods for obtaining them, and of a new method for preparing Polymorph I already known in the literature. 123.-. (canceled)24. A method for obtaining crystalline 2′-O-Fucosyllactose (2′FL) , the method comprising:providing 2′FL in an aqueous solution comprising (i) water and (ii) the 2′FL dissolved therein;adding a crystallization solvent to the aqueous solution over a period of 1 hr to 15 hr, thereby crystallizing the 2′FL and forming 2′FL crystals suspended in the aqueous solution;separating the 2′FL crystals from the aqueous solution to collect solid 2′FL crystals; anddrying the solid 2′FL crystals.25. The method of claim 24 , wherein providing the aqueous solution comprises dissolving in the water a 2′FL hydrate in form of polymorph A with molecular formula CHO.nHO wherein n is 3/2.26. The method of claim 24 , wherein providing the aqueous solution comprises dissolving in the water a 2′FL form selected from the group consisting of 2′FL polymorph A claim 24 , 2′FL polymorph B claim 24 , 2′FL polymorph C claim 24 , 2′FL polymorph I claim 24 , 2′FL polymorph II claim 24 , amorphous 2′FL claim 24 , and combinations thereof.27. The method of claim 24 , further comprising:performing a synthesis procedure selected from the group consisting of extraction, enzymatic synthesis, chemical synthesis, and combinations thereof to obtain the 2′FL that is then dissolved in the water to provide the aqueous solution.28. The method of claim 24 , wherein the aqueous solution is in the form or a syrup having a 2′FL concentration in a range of 50 wt. % to 80 wt. %.29. The method of claim 24 , wherein the crystallization solvent is selected from the group consisting of alcohols claim 24 , ketones claim 24 , nitriles claim 24 , organic acids claim 24 , esters claim 24 , and combinations ...

Подробнее
08-05-2014 дата публикации

Process for the Preparation of ß-C-Aryl Glucosides

Номер: US20140128595A1
Принадлежит: ScinoPharm Taiwan, Ltd.

The present invention provides processes for stereoselectively preparing C-arylglucosides that can be useful as synthetic building block or drugs, including SGLT2 inhibitors. 2. A process in accordance with claim 1 , wherein said metalated aryl compound represented by the formula [ArMY]M claim 1 , whereinAr is a member selected from the group consisting of an aromatic ring, an aromatic heterocyclic ring, a biaryl ring system, a fused aromatic ring, a polyaromatic system, two or more aromatic rings bridged by a methylene group, and a meta-substituted diarylmethane system;{'sup': '1', 'Mis selected from the group consisting of metals, metalloids, poor metals, alkaline earth metals, and lanthanides;'}{'sup': '1', 'Yis not present, or is one or more anions independently selected from the group consisting of halides, phenoxides, alkoxides, sulfonates, sulfates, carboxylates, carbanions, cyanide and cyanate;'}{'sup': '2', 'Mis not present, or is one or more cations;'}the subscript n is an integer or a non-integer number from 1 to 6;the subscript p is an integer or a non-integer number from 0 to 6, and n+p is the total number of anions;the subscript q is an integer or a non-integer number from 0 to 4, and is the total number of cations; and{'sup': 3', '2', '3', '2, 'sub': 'r', 'wherein the process is optionally carried out in the presence of metallic or non-metallic Lewis acid MY, wherein Mis a metal, a metalloid or a non-metal; Yis an anion; and the subscript r is an integer of from 1 to 7.1'}7. The process according to claim 6 , wherein the metalated aryl compound is represented by the formula [ArMY]M claim 6 , whereinAr is a member selected from the group consisting of an aromatic ring, an aromatic heterocyclic ring, a biaryl ring system, a fused aromatic ring, a polyaromatic system, two or more aromatic rings bridged by a methylene group, and a meta-substituted diarylmethane system;{'sup': '1', 'Mis selected from the group consisting of metals, metalloids poor metals, ...

Подробнее
22-02-2018 дата публикации

TECHNOLOGY FOR EXTRACTING AND PREPARING HIGH-PURITY RAFFINOSE FROM DEFATTED WHEAT GERM

Номер: US20180051047A1
Принадлежит:

The present invention discloses a process for preparing high-purity raffinose from defatted wheat germ comprising the steps of percolate extraction of raffinose from defatted wheat germ, decoloration by extraction from the abstraction liquid, electrodialysis desalination, impurity removal by simulated moving bed, concentration and crystallization, with the absolute purity of raffinose as high as 98% and the recovery up to 75%. The process is not only reliable and easy to operate, but also easy to realize industrial production and control the parameters. 1. A process for preparing high-purity raffinose from defatted wheat germ , the method comprising the follows steps:(1) conducting percolation extraction of the defatted wheat germ, and collecting percolate containing raffinose;(2) concentrating percolate of Step (1) to remove alcohol, dissolving solid substance followed by filtering to insoluble substance, extracting the filtrate with an organic solvent and concentrating the aqueous phase, obtaining a decolored solution;(3) processing the decolored solution of Step (2) with a microporous membrane of a drainage, diluting the solution with water to obtain a pretreatment liquid with 50˜150 mg/mL solid concentration, and desalinating the pretreatment liquid with electrodialysis to obtain a desalination solution;(4) separating the desalination solution of Step (3) with a simulated moving bed, and collecting flow containing raffinose, obtaining a supersaturated syrup by concentrating; and(5) crystallizing the supersaturated syrup and obtaining white crystallization raffinose after drying.2. The process for preparing high-purity raffinose from defatted wheat germ claim 1 , according to claim 1 , characterized in that the volume of solution with dissolving solid substance of step (2) is 20%˜35% of the percolate volume.3. The process for preparing high-purity raffinose from defatted wheat germ claim 1 , according to claim 1 , characterized in that organic solvent of Step (2) ...

Подробнее
22-02-2018 дата публикации

ALKALINE PH-MODIFIED EDIBLE CASEIN-BASED FILMS AND COATINGS, AND METHOD FOR THE MAKING THEREOF

Номер: US20180051062A1
Принадлежит:

Improved casein-based films are produced by adjusting the pH of a film-production suspension. The film-production suspension may contain a casein source, a plasticizer, and optionally a strengthening additive. The adjustment of the pH may be accomplished by the addition of an alkaline additive, such as a base, to achieve a desired pH value. The improved casein-based films have improved physical properties as compared to those produced without a pH-adjusted film-production suspension at least in part due to the chemical and structural changes imparted by the change in pH. 1: A casein-based film , comprising:a casein source;a plasticizer; andan alkaline additive,wherein the film has a melting point temperature at 50% relative humidity of at least 60° C.2: The casein-based film of claim 1 , wherein the film has a storage modulus claim 1 , G′ claim 1 , at 50% relative humidity and 60° C. claim 1 , of at least 150 MPa.3: The casein-based film of claim 1 , wherein the casein source is one of a caseinate claim 1 , a fluid or dried milk product claim 1 , milk protein concentrate claim 1 , micellar casein concentrate claim 1 , and a mixture thereof.4: The casein-based film of claim 1 , wherein the plasticizer is one of glycerol claim 1 , sorbitol claim 1 , propylene glycol claim 1 , polypropylene glycol claim 1 , sucrose claim 1 , and a mixture thereof.5: The casein-based film of claim 1 , wherein the amounts of the casein source and the plasticizer are present in a ratio of casein source:plasticizer being 99:1 to 1:1.6: The casein-based film of claim 1 , further comprising a strengthening additive.7: The casein-based film of claim 6 , wherein the strengthening additive is one of a pectin claim 6 , a polysaccharide claim 6 , a pullulan-microbial polysaccharide claim 6 , a dextrin claim 6 , an oligosaccharides claim 6 , a monosaccharide claim 6 , a disaccharide claim 6 , high fructose corn syrup claim 6 , cellulose claim 6 , hemi-cellulose claim 6 , a gum or the constitutive ...

Подробнее
01-03-2018 дата публикации

METHODS OF PRODUCING SIALOOLIGOSACCHARIDES AND USES THEREOF

Номер: US20180055863A1
Принадлежит:

The present invention provides a method of producing a sialooligosaccharide, which comprises: (1) hydrolyzing a sialoglycoprotein by heating at a temperature from 70 to 90° C. in an alkaline aqueous solution; and (2) purifying the hydrolysate to obtain the sialooligosaccharide, wherein a weight ratio of sialic acid to hexose contained in the resulting sialooligosaccharide is from 0.5 to 0.9. 1. A method of producing a sialooligosaccharide , which comprises:(1) hydrolyzing a sialoglycoprotein by heating at a temperature from 70 to 90° C. in an alkaline aqueous solution; and(2) purifying the hydrolysate to obtain a sialooligosaccharide,wherein a weight ratio of sialic acid to hexose contained in the resulting sialooligosaccharide is from 0.5 to 0.9.2. The method according to claim 1 , wherein the sialoglycoprotein is a mucin-type glycoprotein.3. The method according to claim 1 , wherein the sialoglycoprotein is a mucin-type glycoprotein contained in the nest of the Collocaliini tribe.4. The method according to claim 1 , wherein the alkaline aqueous solution is an aqueous solution of potassium hydroxide.5. The method according to claim 1 , wherein the purification is performed by reverse osmosis membrane filtration or electrodialysis.6. A sialooligosaccharide claim 1 , which is produced by a method comprising:(1) hydrolyzing a sialoglycoprotein by heating at a temperature from 70 to 90° C. in an alkaline aqueous solution; and(2) purifying the hydrolysate to obtain the sialooligosaccharide,wherein a weight ratio of sialic acid to hexose contained in the resulting sialooligosaccharide is from 0.5 to 0.9.7. A method for promoting hair growth claim 6 , which comprises claim 6 , administering an effective amount of the sialooligosaccharide according to to a subject in need thereof.8. A method for promoting skeletal muscle formation claim 6 , which comprises claim 6 , administering an effective amount of the sialooligosaccharide according to to a subject in need thereof. The ...

Подробнее
01-03-2018 дата публикации

Tumor specific oligosaccharide epitopes and use thereof

Номер: US20180055928A1
Автор: Natunen Jari, Satomaa Tero
Принадлежит:

The present invention describes oligosaccharide sequences, which are specifically expressed by human tumors. The present invention is related to a method of determining an oligosaccharide sequence, which comprises a tumor specific terminal N-acetylglucosamine residue, in a biological sample, the presence of said sequence in said sample being an indication of the presence of cancer. The present invention provides antigenic substances comprising said oligosaccharide sequences in a polyvalent form and it further provides diagnostic agents, pharmaceutical compositions and cancer vaccines comprising said oligosaccharide sequences or substances binding to said oligosaccharide sequences. The present invention is also related to methods for the treatment of cancer. 1. A method of treating human cancer , the method comprising a step of administering a pharmaceutical composition comprising a substance binding to a human tumor specific oligosaccharide sequence containing a terminal protein linked GlcNAcβ structure or a terminal protein linked GlcNAcβ glycan structure to a human patient suffering from cancer.2. The method of claim 1 , wherein said human cancer is a human tumor and said human tumor specific oligosaccharide sequence is expressed on the cell surface or tissue surface of said human tumor.3. The method of claim 1 , wherein said substance is an antibody claim 1 , a human antibody claim 1 , or a humanized antibody claim 1 , a lectin claim 1 , or a fragment thereof.4. The method of claim 2 , wherein said human tumor is diagnosed to express increased amounts of said human tumor specific oligosaccharide sequence when compared to patient's normal tissue.5. The method of claim 1 , wherein said oligosaccharide sequence has the sequence according to Formula{'br': None, 'sub': s1', 's2, '[GlcNAcβx/Galβ3](GlcNAcβ1-6)Sacch'}wherein x is 3, when Sacch is GalNAc;or x is 2, when Sacch is Man; and whereins1 and s2 are independently 0 or 1 with the proviso that there is at least one ...

Подробнее
04-03-2021 дата публикации

RAPID-ACTING INSULIN FORMULATION COMPRISING A SUBSTITUTED ANIONIC COMPOUND

Номер: US20210060133A1
Принадлежит:

A composition in aqueous solution includes insulin and at least one substituted anionic compound chosen from substituted anionic compounds consisting of a backbone formed from a discrete number u of between 1 and 8 (1≤u≤8) of identical or different saccharide units, linked via identical or different glycoside bonds, the saccharide units being chosen from the group consisting of hexoses, in cyclic form or in open reduced form, said compound comprising partially substituted carboxyl functional groups, the unsubstituted carboxyl functional groups being salifiable. A pharmaceutical formulation including the composition is also set forth. 1. A rapid acting insulin lispro pharmaceutical composition suitable for injection and having a pH of 7.4±0.4 , comprising:an insulin lispro in hexameric form; wherein the insulin has a concentration between 100 to 200 IU/mL;{'sup': +', '+', '2+', '2+, 'a polyanionic compound in a concentration between 10 and 30 mM, wherein the polyanionic compound is citric acid or the Na, K, Ca or Mg salt thereof;'}a preservative;a tonicity agent;{'sup': 2', '−1, 'the insulin pharmaceutical composition having a circular dichroism signal at 251 nm at or below −300 deg cmdmol.'}2. The rapid acting insulin lispro pharmaceutical composition of claim 1 , wherein the pharmaceutical composition does not include EDTA.3. The rapid acting insulin lispro pharmaceutical composition of claim 1 , wherein the tonicity agent is selected from the group consisting of glycerol claim 1 , sodium chloride (NaCl) claim 1 , mannitol and glycine.4. The rapid acting insulin lispro pharmaceutical composition of claim 3 , wherein the tonicity agent is sodium chloride.5. The rapid acting insulin lispro pharmaceutical composition of claim 5 , further comprising zinc salts.6. The rapid acting insulin lispro pharmaceutical composition of claim 1 , wherein the preservative is m-cresol.7. The rapid acting insulin lispro pharmaceutical composition of claim 5 , further comprising a ...

Подробнее
03-03-2016 дата публикации

HYDRATED AND ANHYDROUS POLYMORPHS OF 2'-O-FUCOSSYLLACTOSE AND THEIR PRODUCTION METHODS

Номер: US20160060283A1
Принадлежит:

This invention describes new hydrated and anhydrous polymorphs of 2′-O-fucosyllactose (2′FL): Polymorph A 2′FL-3/2 HO, Polymorph B 2 TL-5/2 HO and anhydrous Polymorph C. There is also a description of the methods for obtaining them, and of a new method for preparing Polymorph I already known in the literature. 1. 2′-O-Fucosyllactose (2′FL) hydrate with molecular formula CHO·nHOwherein n is a number in the range between 1 and 3.2. 2′FL according to claim 1 , wherein n is 3/2.3. 2′FL according to claim 2 , in crystalline form of polymorph A claim 2 , wherein said polymorph A is 2′FL·3/2 HO claim 2 , having characteristic XRPD peaks at 18.86±0.20 claim 2 , 9.89+0.20 claim 2 , 17.05±0.20 20.4. A polymorph A according to claim 3 , having characteristic XRPD peaks at 18.86±0.20 claim 3 , 9.89±0.20 claim 3 , 17.05+0.20 claim 3 , 21.65±0.2 claim 3 , 14.20+0.20 20.5. A polymorph A according to claim 3 , wherein the single crystal has a P222spatial group which is arranged within an orthorhombic crystalline system and the elementary cell has the following parameters: a=12.4098(8) Å claim 3 , b=12.737(2) Å claim 3 , c=13.756(2) Å and a volume of 2212.5 Å.6. A polymorph A according to claim 3 , having anomeric conformation.7. A method for obtaining the polymorph A claim 3 , according to claim 3 , said method comprising the crystallization of 2′FL from a mixture comprising water and at least one solvent claim 3 , wherein said solvent may be selected from alcohols claim 3 , ketones claim 3 , nitriles claim 3 , organic acids claim 3 , esters.8. A method according to claim 7 , wherein the solvent is selected from C 1-C3 alcohol.9. A method according to claim 7 , wherein the quantity of water with respect to the solvent may range between 40 and 10% (v/v).10. 2′FL according to claim 1 , wherein n is 5/2.11. 2′FL according to claim 10 , in crystalline form of polymorph B claim 10 , wherein said polymorph B is 2′FL·5/2 HO claim 10 , having characteristic XRPD peaks at 9.96±0.20 claim 10 ...

Подробнее
21-02-2019 дата публикации

IONIC LIQUID SUPPORTED SYNTHESIS

Номер: US20190055276A1
Принадлежит:

The present invention relates to ionic liquids for use in chemical applications and capable of serving the dual function of solvent and liquid support. The ionic liquid lends itself to a method of synthesizing oligomers selected from the group consisting of oligopeptides, oligosaccharides and oligonucleotides, comprising contacting a first monomer unit with an ionic liquid at reaction conditions to provide an ionic liquid bound monomer unit; and contacting the ionic liquid bound monomer unit with at least one further monomer unit at reaction conditions to provide an ionic liquid bound oligomer comprising from 2 to 30 monomer units. The method lends itself to large scale manufacture of oligopeptides, oligosaccharides and oligonucleotides. 131-. (canceled)32. A kit comprising at least one ionic liquid , wherein the ionic liquid is an organic salt comprising:a heterocyclic or substituted heterocyclic quaternary nitrogen-containing organic cation, a heterocyclic or substituted heterocyclic quaternary phosphonium containing organic cation, or a heterocyclic or substituted heterocyclic trivalent sulfonium containing organic cation, andan anion balancing the charge on the organic cation,and monomeric units selected from amino acids, saccharides and nucleotides.33. The kit of claim 32 , suitable for producing an oligopeptide claim 32 , an oligosaccharide or an oligonucleotide comprising at least 2 monomeric units.34. An article of manufacture comprising at least one ionic liquid claim 32 , wherein the ionic liquid is an organic salt comprising:a heterocyclic or substituted heterocyclic quaternary nitrogen-containing organic cation, a heterocyclic or substituted heterocyclic quaternary phosphonium containing organic cation, or a heterocyclic or substituted heterocyclic trivalent sulfonium containing organic cation, andan anion balancing the charge on the organic cation,and further comprising monomeric units selected from amino acids, saccharides and nucleotides.35. The ...

Подробнее
01-03-2018 дата публикации

PROCESSES FOR PRODUCING MATERIALS HAVING A ZEOLITE-TYPE FRAMEWORK WITH HETEROATOMS INCORPORATED THEREIN

Номер: US20180057364A1
Принадлежит:

A process of producing a zeotype material having a zeolite-type framework. The process includes providing a zeolite having a framework, dealuminating the zeolite to remove aluminum atoms therefrom to produce a dealuminated framework comprising a plurality of vacancy sites, contacting the dealuminated framework with dichloromethane and a precursor comprising heteroatoms, and then heating the dealuminated framework, the dichloromethane, and the precursor under reflux conditions to incorporate the heteroatoms into at least some of the plurality of vacancy sites in the dealuminated framework to produce a zeotype material having a zeolite-type framework comprising the heteroatoms. In addition, a process is provided for producing a stannosilicate comprising a zeolite-type framework comprising Sn heteroatoms incorporated therein which form Sn sites in the zeolite-type framework each having an open configuration or a closed configuration. This process includes controlling relative amounts of Sn sites having open and closed configurations in the stannosilicate. 1. A process comprising:providing a zeolite having a framework;dealuminating the zeolite to remove aluminum atoms therefrom to produce a dealuminated framework comprising a plurality of vacancy sites;contacting the dealuminated framework with a polar aprotic solvent and a precursor comprising heteroatoms; and thenheating the dealuminated framework, the solvent, and the precursor under reflux conditions to incorporate the heteroatoms into at least some of the plurality of vacancy sites in the dealuminated framework to produce a zeotype material having a zeolite-type framework comprising the heteroatoms.2. The process of claim 1 , wherein the solvent is dichloromethane.3. The process of claim 1 , wherein the heteroatoms are Sn or Ti.4. The process of claim 1 , wherein the framework of the zeolite has a Beta topology.5. The process of claim 1 , wherein the heteroatoms are incorporated into more than ninety percent of the ...

Подробнее
04-03-2021 дата публикации

PROCESS FOR EFFICIENT PURIFICATION OF NEUTRAL HUMAN MILK OLIGOSACCHARIDES (HMOs) FROM MICROBIAL FERMENTATION

Номер: US20210061836A1
Автор: Jennewein Stefan
Принадлежит:

The present application discloses a simple process for the purification of neutral human milk oligosaccharides (HMOs) produced by microbial fermentation. The process uses a combination of cationic ion exchanger treatment, an anionic ion exchanger treatment, and a nanofiltration and/or electrodialysis step, which allows efficient purification of large quantities of neutral HMOs at high purity. Contrary to the purification currently used in fermentative production of neutral HMOs, the presented process allows the provision of HMOs without the need of a chromatographic separation. The so purified HMOs may be obtained in solid form by spray drying, as crystalline material or as sterile filtered concentrate. The provided HMOs are free of proteins and recombinant material originating from the used recombinant microbial strains and thus very well-suited for use in food, medical food and feed (e.g. pet food) applications. 2. The process of claim 1 , wherein the separating step i) is performed using ultrafiltration using a cross-flow filter.3. The process of claim 1 , wherein the separated fermentation broth obtained in step i) is diafiltrated before step ii).4. The process of claim 3 , further comprising subjecting the solution to electrodialysis before or after step v).5. The process of claim 4 , further comprising concentrating the purified solution by vacuum evaporation or reverse osmosis.6E. coli.. The process of claim 4 , further comprising adding a ß-glucosidase to the fermentation broth prior to step i). The process of claim 4 , wherein the microbe is recombinant8. The process of claim 1 , wherein the yield of the purified HMO is about 70% relative to the concentration of the neutral HMO in the fermentation broth.10. The process of claim 9 , wherein the separating step i) is performed using ultrafiltration using a cross-flow filter.11. The process of claim 9 , wherein the separated fermentation broth obtained in step i) is diafiltrated before step ii).12. The process ...

Подробнее
04-03-2021 дата публикации

DNA GRIDIRON COMPOSITIONS AND METHODS

Номер: US20210061845A1
Автор: HAN Dongran, YAN Hao
Принадлежит:

Novel compositions and methods for engineering wireframe architectures and scaffolds of increasing complexity by creating gridiron-like DNA structures (FIG. ). A series of four-arm junctions are used as vertices within a network of double-helical DNA fragments. Deliberate distortion of the junctions from their most relaxed conformations ensures that a scaffold strand can traverse through individual vertices in multiple directions. DNA gridirons, ranging from two-dimensional arrays with reconfigurability to multilayer and three-dimensional structures and curved objects, can be assembled according the methods presented herein. 19-. (canceled)10. A composition comprising a plurality of immobile Holliday junction analogs linked together in a plurality of layered frames , wherein each layer of frame has at least two DNA helices which lie on opposite sides of the Holliday junction which also lie in the same plane , and wherein said plurality of immobile Holliday junction analogs are linked together with a central strand of single-stranded DNA within said layer of frame.11. The composition of claim 10 , wherein each layer of frame is independently selected from a hexagonal claim 10 , rectangular claim 10 , or parallelogram shape.12. The composition of claim 10 , wherein said plurality of immobile Holliday junction analogs are linked together in a frame having at least three layers.13. The composition of claim 10 , wherein said plurality of immobile Holliday junction analogs are linked together in a frame having at least four layers.14. The composition of claim 10 , wherein said single stranded DNA comprises M13mp18 DNA.15. The composition of claim 10 , wherein the multi-layered frame having at least three layers comprises a lattice defined by the lengths of said lattice claim 10 , and the interstitial space confined by the lattice defines a cavity claim 10 ,wherein the lattice comprises at least three double-stranded DNA strands, each of which has an independent length.16. ...

Подробнее
22-05-2014 дата публикации

Process for the preparation of (2r,3s)-2-(hydroxymethyl)-5-methoxytetrahydrofuran-3-ol and acetylated derivatives thereof, free of pyranose compounds

Номер: US20140142296A1
Автор: Albercht Zumbrunn, Xing FU
Принадлежит: JOHNSON MATTHEY PLC

The invention provides methyl-2-deoxyriboside containing at most 5 wt % of methyl-2-deoxyribopyranoside, based on the combined weight of methyl-2-deoxyriboside and methyl-2-deoxyribopyranoside.

Подробнее
08-03-2018 дата публикации

COMPOSITION COMPRISING SIALLYLLACTOSE FOR USE IN ENHANCING LEARNING SKILLS AND MEMORY FUNCTION

Номер: US20180064152A1
Принадлежит:

This invention relates to the use of a nutritional composition comprising sialylated oligosaccharides for enhancing cognitive development and learning skills in mammals. The nutritional composition comprises 3′-Siallylactose (3′-SL) and 6′-Siallylactose (6′-SL) in a weight ratio between 10:1 and 1:10 and is specifically for use in enhancing learning skills and/or enhancing memory function in an individual by increasing the sialic acid (Neu5Ac) concentration in the brain of said individual. 1. A method for enhancing learning skills , enhancing memory function in an individual , by increasing the sialic acid (Neu5Ac) concentration in the brain of the individual comprising administering a nutritional composition comprising 3′-Siallylactose (3′-SL) and 6′-Siallylactose (6′-SL) in a weight ratio between 10:1 and 1:10 to an individual in need of same.2. Method according to claim 1 , wherein 3′-Siallylactose (3′-SL) and 6′-Siallylactose (6′-SL) are in a weight ratio between 10:1 and 2:1.3. (canceled)4. Method according to claim 1 , wherein 3′-Siallylactose (3′-SL) and 6′-Siallylactose (6′-SL) are in an amount of from 50 mg to 2500 mg of total sialyllactose per L of the nutritional composition.5. Method according to claim 1 , wherein the nutritional composition is administered to the individual during the early age of the individual.6. (canceled)7. Method according to claim 1 , wherein 3′-Siallylactose (3′-SL) and 6′-Siallylactose (6′-SL) are administered to the individual during the first two weeks after birth in an amount effective to provide from 140 mg to 180 mg in an amount effective to provide from 110 mg to 150 mg.8. Method according to claim 1 , wherein 3′-Sialyllactose (3′-SL) and 6′-Sialyllactose (6′-SL) are administered to the individual in an amount corresponding to from 350 mg to 530 mg of N-Acetyl-neuraminic acid (Neu5Ac) per kg body weight per day.9. (canceled)10. Method according to claim 1 , wherein increasing the sialic acid (Neu5Ac) concentration in the ...

Подробнее
28-02-2019 дата публикации

REGIOSELECTIVE SILYL EXCHANGE OF PER-SILYLATED OLIGOSACCHARIDES

Номер: US20190062361A1
Принадлежит:

The present invention provides novel, regioselectively-acylated oligosaccharide compounds and methods for preparing them. In another aspect, the. invention provides a method for preparing a selectively-acylated oligosaccharide. The method includes forming a reaction mixture containing a protected oligosaccharide and an acylating agent. The protected oligosaccharide includes at least three hydroxyl moieties and each hydroxyl moiety is protected with a silyl protecting group. The reaction mixture is formed under conditions sufficient to selectively replace at least one silyl protecting group with a —C(0)-C1_6 alkyl group, and the selectively-acylated oligosaccharide comprises at least one —C(0)-C1_6 alkyl group and at least one silyl protecting group. 2. The compound according to claim 1 , wherein{'sup': 1', '2', '3', '4', '6', '7, 'R, R, R, R, and Rare each independently selected from the group consisting of —OR, the α-linked monosaccharide, and the β-linked monosaccharide;'}{'sup': 1a', '2a', '3a', '4a', '6a', '7, 'R, R, R, R, and Rare each independently selected from the group consisting of —ORand the linking moiety —O—;'}{'sup': 7', '8, 'sub': 1-6', '3, 'each Ris independently selected from the group consisting of —C(O)—Calkyl and —Si(R); and'}{'sup': 1', '2', '3', '4', '6', '1a', '2a', '3a', '4a', '6a', '7', '7', '8, 'sub': '3', 'at least one of R, R, R, R, R, R, R, R, R, and Ris —OR, wherein Ris —Si(R).'}3. The compound according to claim 2 , wherein Ris selected from the group consisting of the α-linked monosaccharide and the β-linked monosaccharide.4. The compound according to claim 3 , wherein one of R claim 3 , Rand Ris the linking moiety —O—.5. The compound according to claim 4 , wherein Ris —OR claim 4 , wherein Ris —C(O)—Calkyl.6. The compound according to claim 5 , wherein at least one of R claim 5 , R claim 5 , R claim 5 , R claim 5 , and Ris —OR claim 5 , wherein Ris —C(O)—Calkyl.7. (canceled)10. The compound according to claim 9 , wherein Ris —C(O)— ...

Подробнее
27-02-2020 дата публикации

HIGH-PURITY D-PSICOSE PREPARATION METHOD

Номер: US20200062792A1
Принадлежит:

A method for preparing high-purity D-psicose, comprising the following steps: (1) centrifuging a fermentation broth of , and then subjecting the bacteria to homogenization to obtain a mixed solution containing D-psicose 3-epimerase; (2) preparing a fructose solution, adding the mixed solution containing D-psicose 3-epimerase to the fructose solution, adjusting the pH, adding cobalt chloride thereto, and performing the reaction at a certain temperature; and feeding the fructose solution to the reaction solution, continuing the reaction, and stopping the reaction, obtaining a crude D-psicose solution; and (3) subjecting the crude D-psicose solution to decolorization, filtration, ion exchange, chromatographic separation, concentration, and then crystallization or drying, obtaining D-psicose. 1. A method for preparing D-psicose , comprising the following steps:{'i': 'Bacillus subtilis', '(1) centrifuging a fermentation broth of , and then subjecting the bacteria to homogenization to obtain a mixed solution containing D-psicose 3-epimerase;'}{'i': Bacillus subtilis', 'Bacillus subtilis, 'said being a strain BLCY-005, which was deposited in the China General Microbiological Culture Collection Center, Institute of Microbiology, Chinese Academy of Sciences (Address: No. 1-3, Beichen West Road, Chaoyang District, Beijing) on Oct. 26, 2016, and has an accession number of CGMCC No. 13152.'}(2) preparing a fructose solution having a mass concentration of 20% to 60%, adding the mixed solution containing D-psicose 3-epimerase to the fructose solution, adjusting the pH to 5.5-6.5, adding 0.001%-0.005% by mass of cobalt chloride thereto, and performing the reaction at 40-60° C. for 10 to 30 hours; and feeding the fructose solution to the reaction solution to maintain the concentration of fructose in the reaction system at 20% to 60%, continuing the reaction for 10 to 30 hours, and stopping the reaction, obtaining a crude D-psicose solution; and(3) subjecting the crude D-psicose ...

Подробнее
09-03-2017 дата публикации

METHOD FOR THE ISOMERIZATION OF GLUCOSE TO FRUCTOSE

Номер: US20170066793A1
Принадлежит:

In various embodiments, the present invention provides methods to isomerize glucose to fructose using abuse. In one embodiment, the method includes catalyzing isomerization of glucose to fructose including combining an effective catalytic amount of a base with glucose in an aqueous medium so that the glucose is isomerized to yield a mixture comprising fructose and glucose. 1. A method comprising:catalyzing isomerization of glucose to fructose comprising combining an effective catalytic amount of a base with glucose in an aqueous medium no that the glucose is isomerized to yield a mixture comprising fructose and glucose.2. The method of claim 1 , wherein the glucose is isomerized to the fructose with about 40-80% selectivity.3. The method of claim 1 , comprising heating the aqueous medium to about 50-150° C.4. The method of claim 3 , comprising heating the aqueous medium for up to about 30 minutes.5. The method of claim 4 , comprising heating the aqueous medium for about 2-10 minutes.6. The method of claim 1 , wherein during the isomerizing claim 1 , the aqueous medium has an initial pH of about 9 to about 14.7. The method of claim 1 , wherein the mol-% ratio of the base to the glucose is about 5-20 mol-%.8. The method of claim 1 , further comprising isolating and converting the fructose to at least one of 5-hydroxymethylfurfural (FEW) claim 1 , 2 claim 1 ,5-furandicarboxylic acid (FDCA) claim 1 , and levulinic acid.9. The method of claim 1 , further comprising treating the fructose with activated carbon to remove colored impurities.10. The method of claim 1 , further comprising adjusting pH to about 4-10 to substantially eliminate yellowing.11. The method of claim 1 , wherein the base is an organic aliphatic amine or organic heterocyclic amine.12. The method of claim 11 , wherein the amine is an aliphatic amine.13. The method of claim 12 , wherein the amine is a tri(C-C)alkylamine claim 12 , wherein each (C-C)alkyl group is independently selected.14. The method of ...

Подробнее
09-03-2017 дата публикации

DNA GRIDIRON COMPOSITIONS AND METHODS

Номер: US20170066796A1
Автор: HAN Dongran, YAN Hao

Novel compositions and methods for engineering wireframe architectures and scaffolds of increasing complexity by creating gridiron-like DNA structures (FIG. ). A series of four-arm junctions are used as vertices within a network of double-helical DNA fragments. Deliberate distortion of the junctions from their most relaxed conformations ensures that a scaffold strand can traverse through individual vertices in multiple directions. DNA gridirons, ranging from two-dimensional arrays with reconfigurability to multilayer and three-dimensional structures and curved objects, can be assembled according the methods presented herein. 1. A composition , comprising:a plurality of immobile Holliday junction analogs linked together in a two-layer square frame in which the helices on opposite sides lie in the same plane.2. A method of forming a DNA gridiron unit , comprising:combining a plurality of scaffold strands and staple strands complementary to said scaffold strand under conditions suitable for the formation of four four-arm junctions linked together in a two-layer square frame in which the helices on opposite sides lie in the same plane.3. The method of claim 2 , wherein said scaffold strands comprise single stranded M13mp18 DNA.4. The method of claim 2 , wherein said scaffold strands are combined with a 10 times molar excess of staple strands in TAE Mg2+ buffer.5. The method of claim 2 , wherein said scaffold strands and staple strands are annealed from 95° C. to 4° C. for a predetermined time.6. A method of forming a DNA origami nanostructure claim 2 , comprising:linking a number of gridiron units of a predetermined sequence of nucleotides under conditions suitable to form a 2D or 3D lattice of a predetermined design.7. A method of forming a DNA origami nanostructure claim 2 , comprising:designing a plurality of DNA sequences corresponding to a desired shape; andassembling said sequences into at least one gridiron unit.8. The method of claim 7 , wherein said designing ...

Подробнее
15-03-2018 дата публикации

COMPOSITION AND PREPARATION AND USES THEREOF FOR PREVENTING AND TREATING DIABETES

Номер: US20180071353A1
Автор: Li Shiming, Tang Wenping
Принадлежит:

Disclosed is a composition for use in the prevention, treatment, and management of diabetes in human and animal subjects that contains 2,3,5,4-tetrahydroxystilbene 2-O-b-glucopyranoside collected from one or more plants selected from the group consisting of genera of plants. 1Fallopia. A composition for use in the prevention , treatment , and management of diabetes in human and animal subjects , comprising 2 ,3 ,5 ,4-tetrahydroxystilbene 2-O-b-glucopyranoside (stilbene glycoside) collected from one or more plants selected from the group consisting of genera of plants.2. The composition of claim 1 , wherein the stilbene glycoside comprises cis-stilbene glycoside and/or trans-stilbene glycoside.3. The composition of claim 1 , wherein the stilbene glycoside comprises 0-99 wt % cis-stilbene glycoside and 100-1 wt % trans-stilbene glycoside.4. The composition of claim 3 , wherein the cis-stilbene glycoside is derived from the trans-stilbene glycoside by exposure to light.5. The composition of claim 4 , wherein the light is UV light.6Polygonum multiflorum. The composition of claim 1 , wherein the plant is (PM).7. The composition of claim 5 , wherein the composition is prepared by:crushing dried roots of PM to powder;extracting the PM powder with an ethanol solution under the room temperature for at least 2 days to obtain an ethanolic extract, the ratio of solution to solid being about 1:10 (v/w);evaporating and concentrating the ethanolic extract under reduced pressure to obtain a dried extract;subjecting the dried extract to macroporous resin chromatography, followed by eluting the resin with ethanol solutions of different concentrations to obtain a first eluant; andevaporating and drying the first eluant under reduced pressure to obtain PM extract powder.8. The composition of claim 6 , wherein the composition is further prepared by:dissolving the PM extract powder in an aqueous solution and placing the solution under light over night; andsubjecting the light-treated ...

Подробнее
24-03-2022 дата публикации

FORMULATION AND METHOD FOR SPRAY-DRYING D-TAGATOSE

Номер: US20220089628A1
Автор: Campbell Heather R.
Принадлежит:

A D-tagatose spray-drying feed formulation is a mixture of D-tagatose and a functional excipient co-dissolved in a solvent to produce a excipient/D-tagatose composite having a glass transition temperature of greater than 30° C. A method of spray-drying D-tagatose includes the steps of (a) preparing the D-tagatose spray-drying formulation, (b) atomizing the D-tagatose spray-drying formulation in a drying chamber containing a hot inert processing gas and evaporating droplets to produce solid particles of excipient/D-tagatose composite and (c) separating and collecting the solid particles of excipient/D-tagatose composite from the processing gas. 1. A D-tagatose spray-drying feed formulation , comprising: a mixture of D-tagatose and a functional polymer excipient co-dissolved in a solvent to produce a excipient/D-tagatose composite having a glass transition temperature of greater than 30° C.2. The D-tagatose spray-drying feed formulation of claim 1 , wherein the glass transition temperature for the excipient/D-tagatose composite is between about 30° C. and about 40° C.3. The D-tagatose spray-drying feed formulation of claim 1 , wherein the glass transition temperature for the excipient/D-tagatose composite is between about 30° C. and about 35° C.4. The D-tagatose spray-drying feed formulation of claim 1 , wherein the functional excipient is selected from a group of excipients consisting of an amorphous polymer claim 1 , a sugar that has an amorphous state claim 1 , hydroxypropylmethylcellulose acetate succinate claim 1 , polyvinylpyrrolidone K90 claim 1 , D-trehalose claim 1 , hydroxypropylmethylcellulose claim 1 , polyvinylpyrrolidone K64 claim 1 , citric acid and combinations thereof.5. The D-tagatose spray-drying feed formulation of claim 1 , wherein D-tagatose and the functional excipient are provided at a weight ratio of about 1:1.6. The D-tagatose spray-drying feed formulation of claim 1 , wherein the solvent comprises a co-solvent system.7. The D-tagatose spray- ...

Подробнее
19-03-2015 дата публикации

ROLLING COMPOUND POWDERS FOR APPLYING ON THE SURFACE OF CHEWING GUM CORE MATERIALS

Номер: US20150079227A1
Принадлежит:

The present invention relates to rolling compound powders comprising hydrogenated or non-hydrogenated isomaltulose for applying to the surface of chewing gum core materials, chewing gum products comprising such rolling compound powders, processes for reducing the stickiness of compositions of chewing gum core materials by using hydrogenated or non-hydrogenated isomaltulose-containing rolling compound powders in chewing gum preparation processes as well as the use of hydrogenated or non-hydrogenated isomaltulose in rolling compound powders for applying to the surface of chewing gum core materials. 1. A rolling compound powder for applying to the surface of a chewing gum core material , wherein the rolling compound powder comprises hydrogenated isomaltulose.2. The rolling compound powder according to claim 1 , comprising at least 70% by weight hydrogenated isomaltulose.3. The rolling compound powder according to claim 1 , comprising at least 0.1% by weight and at most 5% by weight SiO.4. The rolling compound powder according to claim 1 , comprising around 2% by weight SiO.5. The rolling compound powder according to claim 1 , comprising at most 50% by weight talcum.6. The rolling compound powder according to claim 1 , comprising no talcum.7. The rolling compound powder according to claim 1 , comprising at least 1% by weight and at most 80% by weight rice starch.8. The rolling compound powder according to claim 1 , comprising at least 20% by weight and at most 60% by weight native rice starch.9. The rolling compound powder according to claim 1 , comprising no sugar alcohol selected from the group consisting of mannitol claim 1 , xylitol claim 1 , sorbitol claim 1 , erythritol and mixtures thereof.10. The rolling compound powder according to in combination with a chewing gum core material claim 1 , wherein a layer comprising the rolling compound is present on a surface of the chewing gum core material.11. A process for reducing the stickiness of a composition of a ...

Подробнее
18-03-2021 дата публикации

SYNTHETIC COMPOSITION AND METHOD FOR MODULATING BRAIN FUNCTION AND BEHAVIOUR

Номер: US20210077513A1
Принадлежит:

A synthetic composition for use in improving one or more co-morbid mental disorder symptoms of a patient with IBS, characterised in that the composition contains an effective amount of one or more neutral human milk oligosaccharides, is disclosed. 117.-. (canceled)18BifidobacteriumB. adolescentis. A method for treating anxiety in a patient with irritable bowel syndrome (IBS) , comprising orally administering to the patient an effective amount of a synthetic composition comprising one or more neutral human milk oligosaccharides (HMOs) , wherein the amount is effective to increase the abundance of of the phylogenetic group in the IBS patient.19. The method according to claim 18 , wherein the patient is administered a higher amount of the one or more neutral HMOs for an initial treatment period claim 18 , followed by a lower amount of the one or more neutral HMOs claim 18 , for a maintenance period.20. The method according to claim 18 , wherein the neutral HMO is selected from the group consisting of 2′-fucosyllactose (2′-FL) claim 18 , 3-fucosyllactose (3-FL) claim 18 , difucosyllactose (DFL) claim 18 , lacto-N-tetraose (LNT) claim 18 , lacto-N-neotetraose (LNnT) and lacto-N-fucopentaose I (LNFP-I).21. The method according to claim 18 , wherein the synthetic composition comprises one or more neutral non-fucosylated HMOs and one or more neutral fucosylated HMOs.22. The method according to claim 21 , wherein the synthetic composition comprises 2′-FL and/or DFL claim 21 , and LNnT and/or LNT.23BifidobacteriumB. adolescentisBifidobacterium adolescentisBifidobacterium pseudocatenulatum.. The method according to claim 18 , wherein the of the phylogenetic group is and/or24. The method of claim 18 , wherein the patient exhibits one or more symptoms of depression claim 18 , stress claim 18 , bacterial overgrowth claim 18 , dysbiosis claim 18 , or impaired mucosal barrier.25. A method for treating anxiety in a patient with irritable bowel syndrome (IBS) claim 18 , comprising ...

Подробнее
05-03-2020 дата публикации

METHOD FOR PRODUCING ANHYDROUS GALACTOSE DERIVED FROM SEAWEED

Номер: US20200071737A1

The present invention relates to a method for producing anhydrous galactose derived from seaweed, and provides an improved production yield rate of 3,6-anhydro-L-galactose by using microorganisms during acid treatment, neutralization, and purification after enzymatic hydrolysis, of agarose or agar. 1. A method of producing agarobiose comprisingallowing agarose or agar used as a substrate in an amount of 10% (w/v) to 37% (w/v) with respect to a dry weight to react with a strong acid at a concentration of 0.1% (w/v) to 5% (w/v) at 80° C. to 140° C. for 5 minutes to 500 minutes and performing neutralization to obtain a reaction product comprising agarobiose, wherein a yield of 5-hydroxymethyl furfural in the reaction product is less than 1.5% (w/w).2. The method of claim 1 , wherein the strong acid comprises one or more selected from the group consisting of phosphoric acid claim 1 , sulfuric acid claim 1 , hydrochloric acid claim 1 , and nitric acid.3. The method of claim 1 , wherein the neutralization is performed by adding a strong base to the strong acid-treated agarose or agar such that a pH of the reaction product is adjusted to 5 to 7.4. The method of claim 3 , wherein the strong base comprises one or more selected from the group consisting of NaOH claim 3 , KOH claim 3 , Ca(OH) claim 3 , and Ba(OH).5. A method of producing 3 claim 3 ,6-anhydro-L-galactose comprising:a step of allowing agarose or agar used as a substrate in an amount of 10% (w/v) to 37% (w/v) with respect to a dry weight to react with a strong acid at a concentration of 0.1% (w/v) to 5% (w/v) at 80° C. to 140° C. for 5 minutes to 500 minutes and performing neutralization to obtain a reaction product comprising agarobiose, wherein a yield of 5-hydroxymethyl furfural in the reaction product is less than 1.5% (w/w);a step of allowing the reaction product to react with agarooligosaccharide hydrolase using agarobiose as a substrate; anda step of culturing a microorganism having an ability to ...

Подробнее
05-06-2014 дата публикации

HIGH PERFORMANCE ACRYLAMIDE ADHESIVES

Номер: US20140155563A1
Принадлежит: EMPIRE TECHNOLOGY DEVELOPMENT LLC

Disclosed are derivatives of (tetrahydropyranyl)methyl acrylamide and polymers derived therefrom, as well as methods of making such compounds and polymers. Adhesives, coatings, and plastics which include such polymers are also described. 2. The compound of wherein the protected hydroxyl group is selected from trimethylsilyl claim 1 , t-butyldimethylsilyl claim 1 , acetyl claim 1 , benzyl claim 1 , benzoyl claim 1 , or methoxymethyl.3. The compound of wherein Rand Rare independently selected from the group consisting of H and a methyl group.4. The compound of wherein Rand Rare independently selected from the group consisting of H claim 1 , a methyl group and an ethyl group.6. The compound of selected fromN-((3,4,5,6-tetrahydroxytetrahydro-2H-pyran-2-yl)methyl)acrylamide orN-((3,4,5,6-tetrahydroxytetrahydro-2H-pyran-2-yl)methyl)methacrylamide.7. The compound of wherein one of R claim 1 , R claim 1 , R claim 1 , and Ris the group of Formula II.9. The compound of selected fromN-((3,4,6-trihydroxy-5-methacrylamidotetrahydro-2H-pyran-2-yl)methyl)methacrylamide,N-((5-acrylamido-3,4,6-trihydroxytetrahydro-2H-pyran-2-yl)methyl)methacrylamide,N-(6-(acrylamidomethyl)-2,4,5-trihydroxytetrahydro-2H-pyran-3-yl)methacrylamide, orN-((5-acrylamido-3,4,6-trihydroxytetrahydro-2H-pyran-2-yl)methyl)acrylamide.11. The compound of wherein Rand Rare independently selected from the group consisting of H and a methyl group.12. The compound of wherein Rand Rare independently selected from the group consisting of H claim 10 , a methyl group and an ethyl group.13. The polymer of wherein one of R claim 10 , R claim 10 , R claim 10 , and Ris a group of Formula II.15. The polymer of wherein the one or more repeating units are derived from one or more compounds selected fromN-((3,4,5,6-tetrahydroxytetrahydro-2H-pyran-2-yl)methyl)acrylamide,N-((3,4,5,6-tetrahydroxytetrahydro-2H-pyran-2-yl)methyl)methacrylamide,N-((3,4,6-trihydroxy-5-methacrylamidotetrahydro-2H-pyran-2-yl)methyl)methacrylamide,N-((5- ...

Подробнее
22-03-2018 дата публикации

DETECTION OF OLIGOSACCHARIDES

Номер: US20180080059A1
Принадлежит:

Provided herein are processes for detecting oligosaccharides in a biological sample. In specific instances, the biological sample is provided from an individual suffering from a disorder associated with abnormal glycosaminoglycan accumulation. 130.-. (canceled)31. A method for determining in an individual , the presence , identity , and/or severity of MPS I disorder , the method comprising:a) generating a biomarker comprising of one or more non-reducing end oligosaccharides, wherein the biomarker is generated by treating a population of glycosaminoglycans, in or isolated from a biological sample from the individual, with at least one digesting glycosaminoglycan lyase, wherein prior to lyase treatment, the biomarker is not present in abundance in samples from individuals with the MPS I disorder relative to individuals without the MPS I disorder; andb) using an analytical instrument to detect the presence of and/or measure the amount of the biomarker produced and displaying or recording the presence of or the measure of the biomarker produced;wherein the presence and/or the measure of the amount of the biomarker are utilized to determine the presence, identity, and/or severity of MPS I disorder; andwherein the biomarker is selected from a group consisting ofFormula I-A: IdoA-GlcNAc;Formula I-B: IdoA-GlcNS;Formula I-C: IdoA-GlcNS6S;{'sub': 3', 'n, 'Formula XII: [IdoA-GalNAc](SOR), wherein n is 0-2;'}{'sub': 3', 'n, 'Formula XXI: [IdoA-GlcN(Ac)m-IdoA](SOR), where m is 0-1 and n is 0-4;'}{'sub': 3', 'n, 'Formula XXII: [IdoA-GlcN(Ac)m-GlcA](SOR), where m is 0-1 and n is 0-3; and'}{'sub': 3', 'n, 'Formula XXIII: [GlcA-GlcN(Ac)m-GlcA](SOR), where m is 0-1 and n is 0-3.'}32. The method of claim 31 , wherein the biomarker is selected from the group consisting of: Formula I-A: IdoA-GlcNAc; Formula I-B: IdoA-GlcNS; Formula I-C: IdoA-GlcNS6S; and Formula XII: [IdoA-GalNAc](SO3R)n claim 31 , wherein n is 0-2.33. The method of claim 31 , wherein the biomarker is selected from the ...

Подробнее
12-06-2014 дата публикации

GLYCOCONJUGATES AND THEIR USE AS POTENTIAL VACCINES AGAINST INFECTION BY SHIGELLA FLEXNERI

Номер: US20140161793A2
Принадлежит:

A conjugate molecule comprising an oligo- or polysaccharide covalently bound to a carrier and its use as potential vaccine against infection by 1. A conjugate molecule comprising an oligo- or polysaccharide selected from the group consisting of:{'sub': x', 'y, '(X)—{B(E)C}—(Y)'}{'sub': x', 'y, '(X)-{(E)CD}-(Y)'}{'sub': x', 'y, '(X)-{AB(E)C}—(Y)'}{'sub': x', 'y, '(X)—{B(E)CD}—(Y)'}{'sub': x', 'y, '(X)-{(E)CDA}-(Y)'}{'sub': x', 'y, '(X)-{DAB(E)C}n-(Y)'}{'sub': x', 'y, '(X)—{B(E)CDA}n-(Y)'}{'sub': x', 'y, '(X)-{(E)CDAB}n-(Y)'}{'sub': x', 'y, '(X)-{AB(E)CD}n-(Y)'}{'sub': x', 'Y, '(X)-{DAB(E)CD}-(Y)'}{'sub': x', 'y, '(X)-{B(E)CDAB(E)C}—(Y)'}wherein:A is an alphaLRhap-(1,2) residueB is an alphaLRhap-(1,3) residueC is an alphaLRhap-(1,3) residueE is an alphaDGlcp-(1,4) residueD is a betaDGlcNAcp-(1,2) residuex and y are independently selected among 0 and 1X and Y are independently selected among A, B, C, D, E, AB, B(E), (E)C, CD, DA, AB(E), B(E)C, (E)CD, CDA, AB(E)C, B(E)CD, (E)CDA, CDAB, DAB(E) and wherein n is an integer comprised between 1 and 10 covalently bound to a carrier.2. A molecule according to wherein n is comprised between 2 and 6.3. A molecule according to wherein the carrier is selected among a protein or a peptide comprising at least one T-cell epitope claim 1 , or a derivative thereof.4. A molecule according to claim 3 , wherein the carrier is the peptide PADRE.5. A molecule according to claim 3 , wherein the carrier is the tetanus toxoid.6. A molecule according to claim 1 , wherein the carrier is biotin.7. A molecule according to claim 1 , wherein the saccharide is directly bound to the carrier.8. A molecule according to claim 1 , wherein the saccharide is bound to the carrier via a spacer.9. A molecule according to claim 1 , wherein the saccharide to carrier ratio is comprised between 1:1 and 30:1.10. A molecule according to claim 1 , wherein the saccharide is selected among the tetrasaccharides and pentasaccharides and their oligomers.11. A molecule ...

Подробнее
31-03-2016 дата публикации

Removing impurities from sugar solutions

Номер: US20160090641A1
Принадлежит: Dow Chemical China Investment Co Ltd

Provided is a process for removing impurities from a solution (S1), wherein said solution (S1) comprises one or more sugar dissolved in an aqueous solvent, wherein said solution (S1) has conductivity at 25° C. of 500 μS/cm or higher, and wherein said process comprises (a) contacting said solution (S1) with a cation exchange resin (R1) to produce a solution (S2) in which 80% or more of the cations are all of the same element (E); and (b) then contacting said solution (S2) with a cation exchange resin (R2) in which, prior to said contacting, 90% or more of acid groups are in the salt form with said element (E). Also provided is a process for producing glycols comprising providing an extract solution by the process of claim 1, and then contacting said solution (S3) with hydrogen and a metal catalyst.

Подробнее
07-04-2016 дата публикации

Aldose-Ketose Transformation for Separation and/or Chemical Conversion of C6 and C5 Sugars from Biomass Materials

Номер: US20160096857A1
Принадлежит: UNIVERSITY OF TOLEDO

Systems for converting aldose sugars to ketose sugars and separating and/or concentrating these sugars using differences in the sugars' abilities to bind to specific affinity ligands are described.

Подробнее
07-04-2016 дата публикации

PROCESS FOR THE CRYSTALLISATION OF A WATER-SOLUBLE COMPOUND

Номер: US20160097321A1
Принадлежит: WAGENINGEN UNIVERSITEIT

A process for the crystallisation of a water-soluble compound is disclosed. The process comprises (a) providing, in a crystallisation vessel, a solution of the water-soluble compound in a mixture of water and a solvent in which the water-soluble compound has a lower solubility than in water; (b) passing vapour phase of the mixture through a sorption zone containing a water vapour sorbent to selectively adsorb water from the vapour phase; (c) recycling a part of the vapour phase to the crystallisation vessel or withdrawing vapour phase depleted in water from the process and adding solvent to the crystallisation vessel; (d) allowing solid crystals of the water-soluble compound to precipitate from the solution; and (e) discharging precipitated solid crystals of the water-soluble compound from the crystallisation vessel and discharging a solution of non-crystallised water-soluble compound in water-solvent mixture from the crystallisation vessel. 1. A process for crystallisation of a water-soluble compound from a solution , comprising:(a) providing, in a crystallisation vessel, a solution of the water-soluble compound in a mixture of water and a solvent, wherein the water-soluble compound has a lower solubility in the solvent than in water;(b) passing vapour phase of the mixture through a sorption zone containing a water vapour sorbent to selectively adsorb water from the vapour phase to obtain a vapour phase depleted in water and enriched in the solvent and water-saturated water vapour sorbent;(c) enriching the mixture in the crystallisation vessel in solvent by (i) recycling at least part of the vapour phase depleted in water and enriched in the solvent to the crystallisation vessel or (ii) withdrawing vapour phase depleted in water from the process and adding solvent from an external source to the crystallisation vessel;(d) allowing solid crystals of the water-soluble compound to precipitate from the solution in the crystallisation vessel at a crystallisation ...

Подробнее
12-05-2022 дата публикации

LIQUID ALLULOSE COMPOSITION

Номер: US20220144878A1
Принадлежит:

The invention relates to an aqueous liquid composition comprising allulose, wherein the weight content of allulose is at least 10 wt.-%, relative to the total weight of the liquid composition; and wherein the weight content of allulose is at least 10 wt.-%, relative to the total content of all carbohydrates that are contained in the liquid composition; and wherein the liquid composition has a viscosity of not more than 200 mPa·s. The invention also relates to the use of the liquid composition comprising allulose in food applications and beverage applications. 2. The liquid composition according to claim 1 , wherein the weight content of allulose is at least 25 wt.-% claim 1 , relative to the total weight of the liquid composition.3. (canceled)4. The liquid composition according to claim 1 , wherein the weight content of allulose is at least 55 wt.-% claim 1 , relative to the total weight of the liquid composition.56-. (canceled)7. The liquid composition according to claim 1 , wherein the weight content of allulose is at least 70 wt.-% claim 1 , relative to the total weight of the liquid composition.812-. (canceled)13. The liquid composition according to claim 1 , wherein the weight content of allulose is at least 30% of that weight content of allulose that would be contained in a fully saturated solution of allulose at ambient conditions.1421-. (canceled)22. The liquid composition according to claim 1 , wherein the weight content of water is not more than 90 wt.-% claim 1 , relative to the total weight of the liquid composition.2324-. (canceled)25. The liquid composition according to claim 1 , wherein the weight content of water is not more than 45 wt.-% claim 1 , relative to the total weight of the liquid composition.2649-. (canceled)50. The liquid composition according to claim 1 , which has a coloring capacity of not more than 1000 EBC.5157-. (canceled)58. The liquid composition according to claim 1 , wherein at least 90% of the allulose are present in form of β- ...

Подробнее
12-05-2022 дата публикации

Methods for labeling eukaryotic cells from a multicellular organism as well as for treating and/or diagnosing a cancer using modified monosaccharide compounds

Номер: US20220146516A1
Автор: Sam Dukan
Принадлежит: Diamidex

The present invention relates to modified monosaccharide compounds implemented in methods for labeling and/or detecting an eukaryotic cell from a multicellular organism. It also relates to such modified monosaccharide compounds implemented in methods for identifying or isolating cancer cells, diagnosing a cancer or for cell therapy.

Подробнее
16-04-2015 дата публикации

ALGIN OLIGOSACCHARIDES AND THE DERIVATIVES THEREOF AS WELL AS THE MANUFACTURE AND THE USE OF THE SAME

Номер: US20150105344A1
Принадлежит:

The invention provides an alginate oligosaccharide and its derivatives with the degree of polymerization ranging from 2 to 22. The alginate oligosaccharide is composed of β-D-mannuronic acid linked by 1,4 glycosidic bonds. The derivatives with the reduced terminal in position 1 of carboxyl radical can be prepared by oxidative degradation. The invention also provides a process for preparing the alginate oligosaccharide and its derivatives, which includes the procedure that an alginate solution is reacted for 2 to 6 h in an autoclave at pH 2˜6 and the temperature of 100˜120° C., and adjusted pH to 7 after the reaction is stopped, after which the resultant oligosaccharide is oxidized in the presence of an oxidant to obtain an oxidative product. The alginate oligosaccharide and its derivatives of the invention can be used in the manufacture of a medicament for the prophylaxis and treatment of AD and diabetes. 3. The alginate oligosaccharide or its derivatives or pharmaceutically-acceptable salts thereof according to claim 1 , characterized in that n is 2-12 claim 1 , preferably n is 4 to 8.4. A process for preparing the alginate oligosaccharide or its derivatives or pharmaceutically-acceptable salts thereof according to claim 1 , which comprises the following steps: an alginate solution is reacted for about 2 to 6 h in an autoclave at pH 2˜6 and the temperature of about 100˜120° C. claim 1 , and adjusted pH to about 7 after the reaction is stopped.5. The process according to claim 4 , characterized in that said alginate is sodium alginate and reacted for 4 h at the condition of pH 4 and 110° C.6. The process according to claim 4 , characterized in that after adjusting pH to about 7 claim 4 , alcohol is added to precipitate; the alcohol precipitate is filtered off with suction claim 4 , dehydrated claim 4 , dried and desalted.7. The process according to claim 4 , characterized in that after the alginate solution reacting for about 2 to 6 h in an autoclave at pH 2˜6 and ...

Подробнее
16-04-2015 дата публикации

SEPARATION PROCESS OF OIL AND SUGARS FROM BIOMASS

Номер: US20150105546A1
Принадлежит:

Process for recovery and separation of sugars and oil from plants where the stems and leaves of such plants have substantial levels of both sugars and oils. 1. A method of recovering oil and sugars from a plant comprising stems and leaves , wherein the stems and leaves each contain oil and sugars , mechanically treating the plant to release liquid comprising the oil and sugars from the stems and leaves, thereby forming a mechanically treated mixture comprising the liquid and solid components, the mechanical treatment being selected from at least one of shredding, crushing and pressing;', 'separating the oil from the liquid, thereby forming an oil-rich stream, the oil separation step being selected from centrifugation, membrane filtration, or solvent extraction; and', 'separating the sugars from the liquid, thereby forming a sugar-rich solution, the sugar separation step being selected from centrifugation or membrane filtration., 'the method comprising2. The method of claim 1 , further comprising purifying the oil-rich stream claim 1 , the oil purification step being selected from physical claim 1 , chemical or biological processes.3. The method of claim 1 , further comprising purifying the sugar-rich solution claim 1 , the sugar-solution purification step being selected from physical claim 1 , chemical or biological processes.4. The method of claim 1 , further comprising treating the solid component in a solid component processing step selected from physical claim 1 , chemical or biological processes.5. The method of wherein the plant is a grass.6. The method of wherein the grass is a saccharinae.7. The method of wherein the saccharinae is sugarcane or sweet sorghum.8. The method of wherein the grass is a modified plant.9. The method of wherein the stems and leaves contain oil in an amount of 0.1 wt % to 20 wt % on a dry matter basis.10. The method of wherein the stems and leaves contain sugars in an amount of 0.1 wt % to 55 wt % on a dry matter basis.11. The method ...

Подробнее
13-04-2017 дата публикации

ELECTROCHEMICAL METHODS AND COMPOUNDS FOR THE DETECTION OF ENZYMES

Номер: US20170102349A1
Принадлежит:

Disclosed are compositions and methods for the electrochemical detection of enzymes, such as enzymes that are indicative of disease, disorders, or pathogens, such as viruses, bacteria, and fungi, or other disorders. These methods can be used in point-of-care diagnostic assays for the detection of disease, disorder, or pathogen (e.g., to identify the strain of pathogen infecting a patient in a healthcare setting). The electrochemical methods described herein can also be used to assess the susceptibility of a pathogen to an antipathogen drug. Also provided are probes suitable for use in conjunction with the methods described herein. 5. The compound of claim 3 , wherein X is claim 3 , in each occurrence —OH.6. The compound of claim 1 , wherein Rand Rare claim 1 , in each occurrence claim 1 , —H.7. The compound of claim 1 , wherein A is —OH.8. The compound of claim 1 , wherein Ris —NHC(═O)CH.9. The compound of claim 1 , wherein L is absent.10. The compound of claim 1 , wherein L is a bivalent linking moiety.12. The compound of claim 1 , wherein L is a polyvalent linking moiety.14. The compound of claim 1 , wherein n is 1.15. The compound of claim 1 , wherein n is from 2 to 8.16. A method of electrochemically detecting an enzyme in a sample comprising:(a) providing a probe comprising a substrate for the enzyme covalently linked to an electrochemically active moiety via a bond that is cleavable by the enzyme;(b) contacting the sample with the probe under conditions effective for enzymatic cleavage of the bond by the enzyme;(c) electrochemically detecting the electrochemically active moiety enzymatically cleaved by the enzyme.1724-. (canceled)25. The method of claim 16 , wherein the enzyme is a pathogen-specific enzyme selected from a viral neuraminidase claim 16 , a reverse transcriptase or protease claim 16 , an isoform of β-lactamase sulfatase claim 16 , a β-glucuronidase claim 16 , a carbapenamase claim 16 , a lysyl aminopeptidase claim 16 , or an α mannoside.2637-. ( ...

Подробнее
04-04-2019 дата публикации

METHOD FOR PREPARING 2'-O-FUCOSYLLACTOSE

Номер: US20190100547A1
Принадлежит:

The present invention relates to a method for preparing 2′-O-fucosyllactose and to the protected fucosyl donor of the formula (I) used in this method. The method comprises reacting the fucose derivative of the formula (I) below with the compound of the general formula (II), in the presence of an activating reagent. In the formulae (I) and (II), the variables are each defined as follows: X is Br or a S-bound radical, namely —SCN, —S(O)—Ror —S—R, wherein Rpreferably is an optionally substituted phenyl, and Rpreferably is C-C-alkyl, 2-oxazolin-2-yl, 2-thiazolin-2-yl, benzoxazol-2-yl, benzothiazol-2-yl or pyridin-2-yl; Rare the same or different and are radicals of the formula SiRRR, wherein R, Rand Rpreferably are each methyl; Ris a C(=O)—Rradical or an SiRRRradical, wherein Ris preferably methyl, phenyl or tert-butyl, and R, Rand R14 preferably are each methyl; Rare the same or different and are C-C-alkyl or together form a linear C-C-alkanediyl, which is unsubstituted or has 1 to 6 methyl groups as substituents; Rare the same or different and are C-C-alkyl or together form a linear C-C-alkanediyl, which is unsubstituted or has 1 to 6 methyl groups as substituents. 123.-. (canceled)25. The method according to claim 24 , wherein X in formula (I) is{'br': None, 'sub': 'n', 'sup': X1', 'X2, '—SCN, —S(O)—Ror —S—R, where'} [{'sub': X1', '1', '4', '1', '4', '1', '4', '1', '4, 'Ris aryl which is unsubstituted or optionally has 1 to 5 substituents selected from halogen, C-C-alkyl, C-C-alkoxy, C-C-haloalkyl and C-C-haloalkoxy, and'}, {'sup': 'X2', 'sub': 1', '6', '1', '6', '1', '4', '1', '4', '1', '4', '1', '4, 'Ris selected from the group consisting of C-C-alkyl, C-C-haloalkyl, benzyl, wherein the phenyl moiety of benzyl is unsubstituted or optionally has 1 to 5 substituents selected from halogen, C-C-alkyl, C-C-alkoxy, C-C-haloalkyl and C-C-haloalkoxy, and 5- or 6-membered heterocyclyl, which bears a nitrogen atom in ortho position relative to the point of attachment and ...

Подробнее